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Abstract
/?-defensins are a family of cationic, cysteine-rich antimicrobial peptide (AMP) components of
the innate immune response to infection. They are expressed both inducibly and constitutively
within vertebrates, insects and plants and antimicrobial action is observed against (both gram
positive and gram negative) bacteria and a subset of enveloped viruses. The antimicrobial
phenomenon is thought to result from membrane permeablisation that depends on key,
electrostatic binding events between defensin and pathogen cell surface. This thesis tackles, in
silico, two components of this structure-activity problem: That of rationally predicting /?-
defensin structure, and that of elucidating the first (presumed) binding events between /?-
defensin and pathogen cell surface. Preliminary results suggest that successful in silico folding
requires a mobile disulphide bond strategy to circumvent kinetic trapping of intermediate states,
and that the mechanism of pathogenic binding involves a complex interplay of hydrogen
bonding, as well as productive electrostatic interactions.
x
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Chapter One
Introduction
1.1. Defensins and immunity
Living creatures have had to evolve sophisticated immunity to counter the ever present threat of
microbes and viruses. A central aspect of the innate* immune system in vertebrates (and other
life forms) is a deadly repertoire of antimicrobial peptides that counter pathogenic invasion and
infectionl s. Defensins9'10 are one member of this repertoire that exhibit antimicrobial activity in
phagocytes, inflammatory body fluids and epithelial secretions9'10. The peptide family is small
(35-45 amino acids in length), cysteine rich, highly cationic and sequence heterogeneous11
(classification is therefore based on characteristic disulphide cross linkages between cysteine
residues rather than sequence).
The mechanism of antimicrobial action of this class of protein is not well understood though
current evidence supports a sequential killing mechanism in which initial binding to cell surface
components is followed by lethal membrane destabilisation12"14.
1.2. Why study defensins?
There is an urgent need for new and better antibiotics to keep pace with the increasing problem
of multidrug resistance in hospitals worldwide (Figure 1.2.1). Defensins are of interest because
insights into their antimicrobial mechanism may pave the way to new and better antibiotics.
Living organisms possess two strategies for dealing with the threat of pathogenic infection: innate
immunity and adaptive immunity. The former strategy involves killing the pathogen before entry to the
host and the latter involves adapting to an infection that has overcome the innate barrier.
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Furthermore, defensins are already present within human serum and treatments based on their
mechanism of action may have fewer adverse side effects than current therapies.
From a protein folding standpoint defensins are interesting because their small size and
conformational restriction makes them (in principle) computationally tractable (compared to
most biological proteins, which are much larger). Furthermore, the peptide family possesses a-
helical and p-sheet secondary structure16"19, a property that permits the mechanism of secondary
structural formation to be studied. Lastly, there are almost no computational studies of
disulphide-bridged systems. Defensins are a good model system with which to investigate cross-
linked, conformationally restricted folding.
Figure 1.2.1. Selected data of antibiotic resistance in American hospitals between the years of
2001 and 2004. There is a marked increase in resistance for Cephalothin, Ampicillin and
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1.3. Summary of research aims
The ultimate, long-term goal of this research is to understand the molecular basis of dcfensin
antimicrobial activity so that a new and effective antibiotic can be developed. Understanding this
process depends, in turn, on understanding the initial interactions between defensin and
pathogen.
A secondary (but related) aim is to develop in silico folding methodologies that predict the
global energy minimum for the defensin family of proteins; doing so will increase the academic
understanding of protein folding and reduce the requirement of expensive NMR and
crystallographic procedures (that are currently used to elucidate defensin structural
characteristics).
Chapter Two and Chapter Three introduce the defensin problem and outline the methodology for
tackling the problem. Chapter Four and Chapter Five deal with rational structure prediction of (3-
defensins whilst Chapter Six and Chapter Seven focus on elucidating the mechanism of defensin
membrane permeation. These research aims are summarised in Table 1.3.
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1. Small size of defensins and restricted conformational
space makes defensins ideal candidates for rational
structure prediction.
2. Structures are currently solved with NMR or
crystallography. An efficient protein folding algorithm





HBD1, HBD2 and HBD3
with suspected binding
partners.
1. A primary aim is to establish molecular basis of defensin
killing mechanism so that a new and effective antibiotic
can be developed.
2. The problem ofmembrane permeablisation is simplified
into a number of initial, presumed events. The first (and
primary focus of this work) is the initial binding of
defensin with Lipid A (a suspected cell surface defensin
binding partner).
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The research presented in this thesis bridges the fields of quantum mechanics, molecular
modelling, biochemistry and immunology. A brief introduction to each area is given in this
Chapter and Chapter Three so that the defensin problem can be considered in its full context.
Defensins, aspects of immunology and bacteria are discussed here (below) and the available
methodology is discussed in Chapter Three.
2.2. Defensins
Defensins are a family of evolutionarily related cysteine rich antimicrobial peptides that exhibit
characteristic p-sheet secondary structure and a specific disulphide bridge connectivity1. The
polypeptides are expressed in vertebrates, insects and plants and are an important component of
the innate immune response to invading pathogens.
Defensins were first discovered in the early 1960s when studies of guinea pig and rabbit
leukocyte lysates revealed a set of broad spectrum antimicrobial peptides that were defined by
their unusually high gel electrophoretic mobility2'3. Structurally similar peptides were later
discovered in human leukocytes in the mid 1980s and the term "defensin" coined as a result of
their perceived role in the host defence mechanism1.
6
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2.2.1. Classification and structure
Mammalian defensins are classified into three subfamilies, a, ft and 6 on the basis of differing
disulphide connectivity (Table 2.2.1.1 and Figure 2.2.1.2)M"\ The 6 family is further
differentiated from the a and /? forms by the fact that the N terminus is covalently attached to the
C terminus, rendering each member of the family a circular peptide6'7. Interestingly, this species
is created post-translationally via splicing of two partial a defensin peptides, each of which
contributes 3 cysteines8, but is not present functionally in human.
The reason for the sequence diversity variation across the defensin family is not perfectly
understood. Both a and (3-defensins have been shown to be subject to positive selection pressure
and so, presumably, have evolved in response to species-specific evolutionary pressures.
Save for the cysteine network already discussed, (3-defensins exhibit low sequence homology9.
The little homology that does exist is confined to three glycine residues and a single, positively
charged lysine or arginine residue that trails the final cysteine (Figure 2.1.1.1). Analysis ofphi-
psi torsion angles indicates that the glycines permit the existence of steep, characteristic (3-
defensin folds.
7
Figure 2.2.1.1. The amino acid sequence alignments of a variety of human and murine /3-
defensins9. Black shading denotes heavily conserved regions and grey areas denote less
conserved regions. Uncoloured regions show no significant homology. Note that the glycine
residue immediately preceding cysteine 4 is highly conserved as is the double glycine pair
between cysteines 1 and 2 (though to a lesser extent). The red ribbon denotes a-helical regions
and the green arrows denote p-sheet regions.
conserved glycines
Cysteine Index
hBD-2 O 1 O D P V T L K G G A I iipvr P R R Y K Q I T G L P G T K C C K K P
hBD-1 D H Y N V S S G G Q L Y S A PI F T K I Q T Y R G K A K C C K
mBD-7 N S K R A Y R E G G E L Q R I G L F H K 1 T N F R F K C C K F Q
mBD-8 N E P V S I R N G G I Q Y R 1 G L R H K 1 T G S P F K C C K
hBO-3 G I I NTLQKYY R V R G G R A V L S L P K E E Q 1 K S T R G R K C C R R K
hBO-4 E F E L D R I G Y G T A R R K K R S Q E Y R 1 R P N T Y A C C L R K
mBD-1 D Q Y K L Q H G G F L R S S PSNTKLQ T K P D K P N C C K S
mBD-2 A E L D H H T N G G Y V R A I P P S A R R P S F P E K N P C C K Y M
mBD-3 I N N P V S L R K G G R WN R 1 G N T R Q 1 S G V P F L K C C K R K
mBD-4 . I N N P I T j MTNGAI WG P P T A F R Q 1 N • G H F K V R C C K 1 R
WD ESLLNRTK
o > >
Table 2.2.1.1 The schematic figures illustrate the key differences in cysteine connectivity
across the subfamily, a defensins have a 1-6, 2-4, 3-5 connectivity, (3 defensins have a 1-5,
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2.2.2. The role of disulphide bridges
Defensins exhibit low sequence homology with one another (typically less than 35%) but have
disulphide bridge networks that are highly conserved97'98. The central dogma of biology is that
structure is related to function and the initial assumption with defensins was that their disulphide
bridge connectivity (and associated structure) was a direct requirement for their antimicrobial
activity. The emerging picture however, challenges this biological assumption. The first
evidence of this contradiction was born out by Wu et al who, in 2003, illustrated that peptide
fragments sharing sequence homology with portions of HBD3 were antimicrobially active".
Interestingly, the killing ability of these peptides correlated strongly with cationic charge.
Furthermore, HBD3 molecules that had been entirely reduced* exhibited similar levels of killing
to that of the canonically connected form". This finding implies that charge, and not structure, is
important for antimicrobial action. However, in contrast to this, human neutrophils a-defensins
are known to be inactive in their reduced form12. These findings raise two important questions:
Do a and (3-defensins have different mechanisms of action? And, why have disulphide bridges
been conserved in (3-defensins if their presence isn't required for antimicrobial activity?
When considering the answers to these problems it is important to remember that defensins exist
and participate in a complex and intermeshed biological environment. The disulphide bonds
might be required (for example) to protect the backbone from proteolysis during biosynthesis, or
to perform other secondary functions11'13 (Section 2.2.6).
Figure 2.2.2.1 shows the disulphide bridge networks in HBD1 and FTNP3.
The term "reduced" refers to a cysteine that is covalently bonded to hydrogen, rather than being involved
in a disulphide bridge.
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Figure 2.2.2.1. Typical structures for an a and fi-defensin shown in a cartoon representation.
Arrows represent /3-sheets and ribbons represent a-helices. Bisulphide cross linking is shown in
yellow with a "liquorice" representation. A, The Crystal structure of the a-defensin HNP310. B, A
representative native NMR structure of the (3-defensin HBD19.
2.2.3. Where are defensins expressed?
Within vertebrates, defensins are expressed both intracellularly and extracellularly. The specific
locations and relative intensities of expression vary across mammalian species, a phenomenon
which is thought to result from pathogen specific evolutionary pressures. Rabbits for example,
are the only animals known to have high levels of a-defensins in their alveolar macrophages14,
whilst the leukocytes of mice (in contrast to all other examined species) exhibit no defensin
expression whatsoever1'.
a) Intracellular secretion
In an intracellular setting defensins form part of a cocktail of antimicrobial
ingredients that phagocytes utilise to kill engulfed organisms. The defensins are
stored in intracellular compartments (or "granules") where they become highly
10
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concentrated (often in excess of 10mg ml"1). When a foreign particle is engulfed the
intracellular granules fuse with the vacuole housing the invading microbe and the
internal contents of the granule released in order to obliterate the pathogen116"18.
b) Extracellular secretion
Extracellular secretion is known to occur on skin, in the respiratory system, in the
reproductive system and at base levels within most (if not all) mucosal secretions.
Keratinocytes within human skin secrete at least 3 types of (3-defensins (HBD1,2
and 3)19 20 2l. The respiratory system is protected by the same three defensins, with
sub epithelial glands of the respiratory system exhibiting similar patterns of
expression to skin22"25. In the digestive system Human Paneth cells (specialized
epithelial cells that line the crypts of the small intestine) secrete a-defensins in
response to bacterial challenge26. Indeed, work by Wilson et al. illustrate that
knockout mice for a-defensin activity are less able to control ingested bacterial
challenges from E.coli and S.enterica21.
2.2.4. Genetic control and synthesis
Genes for both a and (3-defensins are housed in the p23 region of chromosome 825"32.
Bioinformatic exploration of the human genome has resulted in other defensin gene clusters
being found in other chromosome locations33. Notably Motzkus et al., in 2006, synthesised a
novel (3-defensin (DEFB123) from bioinformatic information34.
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Defensins are synthesised as inactive precursor molecules that consist of a signal sequence, a
"propeptide" region and a "normal" defensin region33 (Figure 2.2.4.1). Post-translational
modification of the inactive precursor yields the biologically functional species.
Figure 2.2.4.1. A schematic representation of a defensin being transcribed and translated. The
mRNA is produced from various exons and the signal and pro regions removed post-
translationally to produce the active protein35







Defensins exhibit both constitutive and inducible expression in a manner that often depends on
their specific localisation. HBD1, for example, is expressed constitutively in airway epithelia36
but expressed inducibly in monocytes37. Similarly, expression of HBD2-4 is induced by
proinflammatory cytokines such as IL-1[3 , LPS and TNF-gt 3s'39. Recent work has shown that
the mKNA ofHBD2 in oral epithelial cells is upregulated in response to microbial proteases40, a
finding that indicates the existence of other modes of regulation.
12
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2.2.5. Mechanism of antimicrobial action
Understanding the molecular basis for defensin antimicrobial activity is a central aim of this
research and Chapter Six and Chapter Seven treat the problem in greater depth. The challenge is
formidable. Different defensins kill different organisms under different conditions, implying that
there is more than one killing pathway. Accordingly (and frustratingly) insights gained from the
mechanism of one defensin do not necessarily map to the killing mechanism of another. Most
antimicrobial peptides exhibit high levels of cationic charge and there is consensus that this
property is connected with their ability to attack and permeablise pathogenic membranes7'41"44,
though some antimicrobial peptides such as alamethicin are known to kill despite being charge
neutral45. There are two models for (3-defensin antimicrobial activity (Figure 2.2.5.1)-.
a) The carpet model46
In this model defensins are presumed to accumulate on the target surface. When a
threshold concentration is reached the "carpet" destabilises the macromolecular
structure of the underlying membrane. Peptides do not necessarily insert into the
hydrophobic membrane core and ion channels do not necessarily form.
b) The pore model47
In this model defensins are presumed to oligomerise on the cell surface and generate
pores that lethally disrupt the ionic balance of the pathogen. A dynamic process is
thought to follow initial binding in which structural reorganisations of the peptide
complex drives lipid insertion and subsequent pore formation. The hypothesis is
born out of experimental evidence of pore formation in other peptide systems47"49.
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Both these models assume that the defensins permeate the outer membrane freely. This is a
plausible conjecture because the pores in the peptidoglycan component of the outer membrane
are known to be in the region of 2-3 nnf°, large enough to permit such passage.
Figure 2.2.5.1. Models of pore formation by defensins adapted from Sahl et al.52. Step 1: The
outer membrane of the bacteria is crossed. Step 2: The defensins are electrostatically attracted
to the anionic bacterial membrane surface. Step 3: An amphipathic structure capable of
membrane insertion is formed. Step 4: The membrane is permeablised via a carpet or pore
mechanism.
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Whilst both these mechanisms (Figure 2.2.5.1) are plausible, neither provides detail or
quantitive measure (or calculation) of the physical and thermodynamic process at a molecular
level. Are the carpet and pore models energetically realistic given that small, highly cationic
monomers must pack in close proximity? There is tentative evidence that dimerisation is
possible (at least in some defensins). Indeed, recent electrostatic potential calculations on a
variety of defensin homologues suggest that HBD2 is able to exist dimericallyM. Similarly, the
5-cysteine (3-defensin related protein, Defrl. has been experimentally shown to dimerise
covalently via a single, intermolecular disulphide bridge118. The 6 cysteine analogue of this
14
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protein is known to dimerise non-covalently under mass-spectrometric and collision Ion
Dissociation (CID) conditions118. Finally, NMR diffusion spectroscopy of HBD3 suggests
symmetric, non-covalent dimers can form via the B2 strand of the (3-shcet in conditions of 0.1 M
and pH 8119. This same study does, however, indicate that HBD1 and HBD2 remain in
monomeric form under these conditions. It is not yet clear whether the local chemical milieu
surrounding the bacterial surface permits dimerisation (or higher order oligomerisation).
2.2.6. Secondary immune functions
Defensins exist within a complex soup of interacting immune particles and whilst they are highly
antimicrobial, they are also extensively involved in regulating and directing immune (and other)
processes. For example, they stimulate proliferation of epithelial cells53, interfere with signal
transduction pathways84, upregulate cytokine and adhesion molecule expression55 and directly
recruit other immune particles (a process known immunologically as "chemoattraction" or
"chemotaxis")11- This latter role is known to require intact disulphide bridges11. There is even
some evidence that defensins selectively target and destroy tumour cells56.
2.3. Other antimicrobial peptides
Living organisms have evolved an enormous repertoire of defences to deal with the milieu of
environmental pathogens. Defensins are (unsurprisingly) not the only component of this
repertoire. Some specific examples (Figure 2.3.1.1) of other antimicrobial peptides are presented
here:
2.3.1. Cathelicidins57
These are a related family of antimicrobial peptides expressed in Leukocytes and epithelial cells
of the testes, skin and gastrointestinal tract within a variety of mammals (including humans).
15
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Like defensins they are highly charged, active against both gram-negative and gram-positive
bacteria and upregulated in response to inflammatory cytokines. Unlike defensins however, they
have no cysteine residues. In solution they adopt an unstructured coil, but quickly fold into an
alpha helical form on entering hydrophobic environments.
2.3.2. Histatins58
These, like defensins and cathelicidins, are a family of small, cationic peptides (24-38 amino
acids in length). They are histidine rich, possess no cysteine residues and are constitutively
expressed in human saliva. Aqueous environments favour a non-structured linear form whilst
non-aqueous environments favour an alpha-helical fornf9. Furthennore histatins are known to
perform many secondary functions60"64. For example, they downregulate inflammatory cytokines
and fibroblasts60, as well as inhibit various disease-causing bacterial enzymes61.
2.3.3. Magainins47
Magainin antibiotics are a family of immunogenic, cationic peptides (of 21 to 26 amino acids)
found in the skin and intestines of the African Clawed frog (Xenopus Ictevis). Their sigmoidal
relationship between peptide concentration and killing indicate a highly cooperative membrane
permeablisation process66"67. Furthermore, some members of the family are known to kill
synergistically with other members68. In solution they adopt a non-structured coil whilst in non¬
aqueous solvents they exist in extended alpha-helical configurations.
2.3.4. Alamethicin45,69
Alamethicin is a helical 20 amino acid peptide product of the fungus Trichoderma viride. This
peptide gives rise to voltage-dependent conductance across lipid bilayers through a channel
16
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formation process that involves
mammalian analogues, it attacks
molecule is charge neutral.
2.3.5. Melittin69
There are a whole host of other toxins that indiscriminately permeablise both prokaryotic and
eukaryotic membranes. Melittin, for example, is the primary polypeptide component of
European Bee venom. NMR and crystal studies indicate that the peptide adopts two alpha helical
regions that hinge between amino acids 10 and 1270 71. This "hinging" ability in conjunction with
the hydrophobic packing of non-polar groups gives rise to a distorted or "bent" helix. There is no
evidence that this peptide oligomerises, and indeed, the most recent study confirms that melittin
remains monomeric within liquid crystalline bilayers72.
The above peptides have two unifying factors; they are all less than 40 amino acids in length and
all possess some degree of helicity in non-polar environments. The other properties bear
exceptions. Most are highly cationic, though one (alamethicin) is neutral. Some almost certainly
oligomerise, others certainly don't. Some are highly selective for prokaryotic cells, whilst others
attack all membranes indiscriminately. Thus, which properties are responsible for antimicrobial
action? Do they all have similar modes of action? Is charge important for discriminating self
over non-self, or for killing, or for both? There are many questions that need to be answered, and
further treatment of this matter outside of the defensin problem is beyond the scope of this
introduction.
cooperative insertion of peptide monomers. Unlike its
both prokaryotic and eukaryotic cells. Interestingly, the
17
Figure 2.3.1.1. Structures of selected antimicrobial peptides shown in cartoon representation.
Grey shading refers to non-polar residues, green to polar residues, blue to cationic residues and
red to anionic residues. A NMR structure of melittin in methanol71. B Crystal structure of
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2.4. Molecular modelling
In this thesis molecular modelling is divided into two separate problems; that of rational
staicture prediction of defensins, and that of molecular dynamical interactions with the target
membrane (or its components). Molecular modelling techniques are widely used to tackle
• 7S 81 82 89
protein problems ' ~ and are a central research theme (Chapter Three, Chapter Four,
Chapter Five, Chapter Six and Chapter Seven).
2.5. Bacterial membrane structure
The first point of contact between defensins and bacteria occurs at the multi-layered cell
envelope that surrounds the bacteria. Defensins must traverse this layer to target the cytoplasmic
membrane. Accordingly, a mechanism of action must begin with accounting for the binding
event that occurs at the interface of the outer membrane and the external environment. An
understanding of surface components of bacteria is needed and as such a brief outline of
bacterial membrane structure is provided.
All bacteria can broadly be divided into two categories, "gram-positive" and "gram-negative",
on the basis of key differences in cell wall structure. Gram-positive bacteria are characterised by
a double layer membrane whilst gram-negative bacteria are characterised by a triple-layered
membrane. Both cell wall types are here discussed in more detail.
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2.5.1. Gram-negative bacteria
Gram-negative bacteria are characterised by the presence of a triple layered membrane (Figure
2.5.1.1)
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Figure 2.5.1.1. Schematic representation of gram negative cell wall structure (taken from review























Aspects of each layer of the membrane are discussed below:
a) The inner cytoplasmic membrane
The inner layer is a cytoplasmic phospholipid bilayer awash with an array of
proteins required for recognition and transport of various metabolites and synthetic
products into and out of the cell. Its role is highly specialised to dealing with
selective reabsorption.
b) The peptidoglycan layer
Bacteria have been forced to develop means of survival in an external environment
over which they have almost no control. One strategy for dealing with this has been
to develop a mechanically durable and versatile cell wall. Many of these mechanical
20
properties arise from the presence of peptidoglycan, a macromolecular scaffold
constructed from a polymer of N-acetlymuramic (NAM) acid and N-
acetlyglucosamine (NAG) {Figure 2.5.1.2). The peptidoglycan layer surrounds the
entire cell and confers great strength and versatility to the bacterium.
In gram negative bacteria the peptidoglycan layer is approximately 2-10nm thick " and
forms almost 10% of the dry weight of an individual bacterium92. Whilst the structure is
mechanically strong, recent evidence suggest that it is in fact also highly flexible and
capable of expanding and contracting in response to changes in osmotic pressure93.
Peptidoglycan layers have also been found to have large pores approximately 5nm in
diameter (but varying with osmotic conditions) which permit the passage of all
biologically relevant molecules.
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c) The outer membrane
Finally, surrounding the inner membrane and peptidoglycan matrix is a second
phospholipid membrane festooned with an array of surface markers and ion
channels. Since it forms the first site of contact with the external world, the outer
membrane possesses many of the properties responsible for the infective and
pathogenic capability of the organism. One such marker, with particular clinical
relevance is Lipopoysacharide (LPS) (commonly referred to as Endotoxin). It is one
of many markers responsible for aspects of virulence and pathological immune
responses94"98. LPS is particularly relevant to the study of defensins and as such it
will be given further consideration.
d) The periplasmic space"
Eukaryotic cells possess an abundance of specialised intracellular organelles for
compartmentalising potentially damaging reactions. Bacteria do not possess such
organelles and as such potentially damaging reactions must take place outside the
cell. Digestive enzymes are translocated from the interior of the bacterium to a small
gap, known as the periplasmic space, which exists between the inner membrane and
the peptidoglycan layer. The digested products then diffuse (or are actively
absorbed) across the inner cytoplasmic membrane.
e) The structure and function of LPS
LPS consists of a phospholipid region and a polysaccharide region. The
phospholipid region contains a functionally vital component known as Lipid
^101.113.114 polysaccharide region is itself often considered as two distinct
entities; the "core region" and the "O-spccific chain", each of which is synthesised
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independently90'111"112. The O-region of the molecule is known to be highly variable,
whilst Lipid A and specific parts of the core region remain largely conserved100.
Figure 2.5.1.3 summarises the structure of the molecule.
Figure 2.5.1.3. Structure of LPS showing O-specific chain, Core region and Lipid A region.
(Taken from review by Alexander and Rietschel9 )
Polysaccharide Phospholipid







Repeating Unit Outer Core Inner Core
i. Lipid A
Lipid A is the primary immunogenic stimulant of the molecule and a number of
modifications to it are known to impart resistance to defensin attack. One such
modification in Salmonella typhimurium arises by addition of 4-deoxy-4-
aminoarabinose (Ara4N) to diglucosamine phosphate residues101 (Figure
2.5.1.4). In addition to strict genetic contributions, serum factors are also known
to produce an assortment of LPS phenotypes. For example, some S.
typhimurium isolates alter their LPS structures in response to changes in serum
levels of Mg2+ ions102'103. Though many structural changes involve the
incorporation of cationic species to the saccharide region, some alterations
involve changes to the membrane bound component104. Indeed, certain strains of
23
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S. Typhimurium are characterized by the presence of palmitate in the lipid
portion. Surprisingly, this alteration also confers resistance to defensins and
other cationic peptides.
The species P. aeruginosa is known to possess similar responses to
environmental conditions. Interestingly, lipid A in serotypes associated with
Cystic Fibrosis were shown to exhibit both altered acyl groups and high levels
of substitution with Ara4N, much like those alterations exhibited by S.
Typhimurium10:.
Figure 2.5.1.4. Structure of Lipid A region showing O-antigen, Core and Lipid A. The
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The Core Region
The inner core region of LPS tends to be more conserved than the outer core
region and, thus, it is likely that the inner core possesses traits essential to LPS
function. In general, the two regions can be distinguished from one another on
the basis of their monosaccharide composition100. The outer core consists
predominantly of hexoses such as D-glucose, D-galactose, D-glucosamine, N-
acetylglucosamine or N-acetylgalactosamine. In contrast, the inner core is
characterized by the presence of 3-deoxy-D-wonno-octulosonic acid (dOclA)
(usually also termed '2-keto-3-deoxyoctulosonic acid' (Kdo)) and L- or D-
glycero-D-/H£777/7<y-heptose (L,D-Hep). These groups are occasionally modified
by additional anionic substituents such as phosphate (P), diphosphate (PP) or
diphosphoethanolamine (PPEtn) groups100. Current proposals posit that the
sugar acid Kdo forms a characteristic and essential component of the inner core
region of bacterial LPS and accordingly provides a diagnostic basis for
characterization100' 107. In the vast majority of gram negative bacteria, a Kdo
residue links the polysaccharide moiety to the lipid A domain via a specific
ketosidic bond that is unusually sensitive to chemical cleavage under acidic
conditions108 109. Mutants associated with changes in the core region are also
known to confer resistance to defensins110.
The O-specific Region
The O-specific chain forms the most structurally heterogeneous portion of LPS.
Indeed, differences in the O-specific region frequently provide the very basis for
classifying serotypes. The synthesis of the O-specific chain in enterobacteria is
25
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determined by the wb* (or rfb) gene cluster111. Bacterial isolates possessing a
dysfunctional (or absent) wb* locus synthesize LPS that possess absent or
malformed O-specific chains. These isolates are capable of developing and
multiplying in vitro and accordingly demonstrate that the O-chain is not
essential for bacterial viability. However, experiments under in vivo conditions
have shown that a variety of pathogenic enterobacteria require O-specific chains
to prevent uptake by phagocytes and attack by serum complement90. It is posited
that this large and relatively cumbersome region of the molecule provides a
shield to attack by elements of the host immune system90.
In addition, a variety of strains from several pathogenic species such as H.
pylori, N. gonorrhoeae, N. meningitidis and H. influenzae have been found to
possess terminal ligosaccharide structures that closely resemble human
glycosphingolipids. This mimicry probably arises due to the presence of
Nacetylneuraminic acid (NeuNAc) or L-fucose (L-Fuc), which are also present
on mammalian cells112.
iv. Concluding Remarks for LPS
The study of LPS has been hampered by the fact that it exhibits enormous
heterogeneity across species and serotype. Furthermore, culturing populations of
bacteria with homogenous LPS is exceedingly difficult because the consistency
of the LPS is highly dependent on the growth medium. Indeed, subtle changes in
external conditions can tilt the microbial environment towards favouring a
mixed bag of LPS structures. Accordingly, developing a practical means of
26
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testing molecular modelling results for a specific serotype against an experiment
that utilises a homogenous serotype is time consuming, fiddly and expensive.
A central aim of this research is to understand the interactions between
defensins and lipid A, and to understand the behaviour of cationic Lipid A




The gram-positive membrane consists only of two layers; the inner phospholipid bilayer and the
outer and relatively much larger peptidoglycan matrix. Protruding from the surface are hundreds
of different surface markers, of which the most abundant and specific to the species are teichoic
acids. Like LPS, teichoic acids impart polyanionic properties on the bacterial surface. Whilst
both molecules possess some similar functional properties, they are also markedly different in a
variety of respects. For example, gram negative bacteria are known to be far more resistant to
intestinal environments in comparison to gram positive bacteria, an observation which is
assigned to the increased shielding properties of LPS components in comparison to TA90.
a) Teichoic Acids
TA constitute between 30% and 60% of the cell wall. Like LPS, TA residues
possess a fatty acid membrane, a core sugar unit and a polymer chain of variable
length (.Figure 2.5.2.1). The repeat region consists of a series of highly anionic
phusphodiesler linked molecules of either 1,3- glycerol-phosphate (-Gro-P-) or 1,5
D-ribitol-phosphate (-Rbo-P-)115116.
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The nature and consistency of peptidoglycan is very similar for both membrane
types. However, gram-positive peptidoglycan is often characterised by a greater
degree of cross-linking.
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Chapter Two outlines the [3-defensin problem and the background needed to understand it. This
Chapter discusses the techniques used to tackle the problem. Molecular mechanical
approximations are outlined, as well as a repertoire of rational structure prediction algorithms
and free-energy methods. Unless otherwise stated, the methods are implemented with the
AMBER 91 force field.
In an ideal world of infinite computational resources researchers would have the luxury of
solving protein folding (and interaction) problems with high-level quantum mechanical
treatments. The reality is that only the smallest molecules (less than one hundred atoms) can
conceivably be tackled in this fashion, and often on time scales that are biologically irrelevant.
The molecular modeller is thus forced to make drastic simplifications. Frequently these are:
1. Ignore any electronic fluctuations: instead, calculate an approximate charge for each
atomic centre based on a single, plausible conformation and assume that this fixed
charge approximates the true, time-averaged electronic distribution (Section 3.2).
2. Treat atoms as semi-hard spheres of differing radii (Section 3.3).
3. Approximate the interactions of these atoms with one another as the sum of
energetic contributions from van der Waals, electrostatic interactions, dihedral
twisting and bond angle terms (Section 3.3)
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In order to achieve step 3 the modeller requires a set of point charges for each of the atomic
centres (to calculate the electrostatic contributions), and a set of constants of proportionality and
atomic radii (to describe the remaining interactions).
3.1.1. Choice of forcefield
The AMBER force field and software implementation is chosen for this research for two
principle reasons:
1. AMBER is widely used (Figure 3.1.1.1) and has in many cases provided excellent
agreement with experiment.
2. The generalised AMBER force field (GAFF) in conjunction with the
"Antechamber" procedure allows novel residues to be developed in an easy,
transparent (and often reproducible) manner2"5.
Figure 3.1.1.1. Publications within the "Web of science" database listed under the
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3.2. Obtaining point charges: The RESP procedure
The electrostatic properties of a molecule are intricately connected to its distribution of electrons
and nuclei. The challenge is to simplify the dynamic electrostatic potential of this complex
system into a single, point-charge representation of a static state. Unfortunately however, a static
charge state cannot be calculated unambiguously from a quantum mechanical wavefunction and
the modeller is thus forced to:
1. Calculate the electrostatic potential for a given system in a given configuration using
quantum mechanical techniques.
2. Sample points from this potential and balance the corresponding charge arising from
these points with a new, single point-charge.
There are many ways of performing these two steps and there is no agreement as to which
strategy is most representative of a real system. The strategy used in this research is that of the
RESP procedure implemented in AMBER 96.
3.2.1. Deriving charges from the molecular electrostatic potential
The electrostatic potential at a point in space is defined as:
"The work done in bringing a unit positive chargefrom infinite displacement to that point."
Under this definition nuclei generate a positive (repulsive) force, whilst electrons generate a
negative (attractive) force. A value for the electrostatic potential, (p, in a given configuration can
be obtained from the wavefunction for the system7:
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<Kr) = <f>nuc, (r) + tec 00 =




Where r represents a given point in Cartesian space for a set of M nuclei of charge ZA (and
displacement RA) interacting with a set of electrons with distribution densityp .
Equation 7 is a continuous function for which there is no analytic solution. For the purpose of
modelling it is necessary to represent this function as a collection of discrete points, the
superposition of which approximate the underlying behavior. One such widely used method for
doing this is the Restrained Electrostatic Potential fit procedure6'8.
3.2.2. Restrained Electrostatic Potential (RESP) charge derivation
The RESP procedure is one of a myriad of tools used to bridge the gap between quantum and
Newtonian mechanics. The method offers a means of mapping the quantum mechanically
derived electrostatic potential onto a set of point charges for each of the atomic centres.
a) The charge fitting procedure6,8"10
The charge fitting process involves spherically encasing a set ofj atoms, each with a
set of / points. The electrostatic potential is then computed for each of the atomic
centres such that a distant dependent charge distribution is generated. A single point
charge qj is subsequently fitted to the centre of each of the j atoms such that the
initial electrostatic potential arising from the / points is exactly balanced. This can
be conveyed mathematically as a least squares problem:
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j^2 jyintrial y calculated J" (2)
Where R is the objective function, V'""al is the initial set of discretised points and
ycaicuhted -g t^e eiectrostatjc potential arising after the point charge qj has been fitted:














Equation 5 above can be recast in an appropriate matrix representation" and solved
for q.
b) Adding restraints
A traditional unrestrained least squares fit of the charge problem (as described
above) frequently overestimates the bond strength in species involving hydrogen
bonding6. This overestimation can effectively be reduced by including a hyperbolic
penalty function within the fitting procedure:
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n2 _ T}2 , n2
adjusted original restrnt VW
Where the hyperbolic function R takes on the form:
r: kres,Yj (q; +b2)2-c (7)
The "tightness" of the hyperbola and its minimum are determined by b and the
extent to which the restraint affects the overall fit is given by krest. The restrained
electrostatic fit is then solved in matrix form in the same manner as the normal ESP
method.
c) Calculating the constants of proportionality for the forcefield equation
The AMBER suite of programs contains a "generalized force field" in which the
parameters for many atomic connectivities have been obtained empirically or
calculated2'12. Thus, for many novel systems (for which there are no "library"
residues) one important challenge is to assign the charge state.
3.3. The forcefield equation1
The sum of atomic interactions can be expressed mathematically as:
E,.,,= ZKr(r-r„)' + +
anglesbonds
K
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The term Etotai represents the energy of the system. The term J*Kr(r - rea)2 represents the
bonds
stretching of covalent bonds from the equilibrium bond length req with a force constant Kr.
The term -9eq)2 refers similarly to displacement from the equilibrium angle 9.
angles
V
The term ^ — [l + cos(n^-/)J encompasses the twisting of angles from the
dihedrals ^
A B
equilibrium position cp. The term ^ jmodels the van der Waals interactions
RU Rii




This energy term is approximated as a quadratic function. The trough of the function
corresponds to the equilibrium bond length and displacement from the equilibrium results in the
energy of the system increasing exponentially. In reality, increasing the distance between bonded
atoms past a certain point results in diminished attraction, and as such the quadratic function is
only valid when considering small displacements from the equilibrium.
3.3.2. Bond angle
The bond angle function measures the extent to which energy varies as the bond angle between
two directly connected atoms changes. This is a quadratic function that describes fluctuations
accurately about small displacements from equilibrium.
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3.3.3. Dihedral bond angle
The dihedral bond angle is a measure of twisting about the equilibrium bond. This function
varies with the cosine of the dihedral angle. The energy function of the system accordingly
oscillates between a maximum and minimum with every 360 degree change in angle.
3.3.4. Van der Waals and electrostatic interactions
The remaining interactions are approximated with the final term of equation 8. Whilst it captures
good general behaviour of atomic interactions, it tends to exaggerate attractive forces in the
region of the minimum. The choice of dielectric constant employed to calculate the interaction
energy depends on the environment of the simulation. Values range from approximately 80 in
water, to 1-4 in the interior of a protein.
3.3.5. The Generalized Born model14"19
Explicit water particles can often make simulations prohibitively time consuming. In many cases
it is far more computationally efficient to replace discrete water molecules with a continuum that
possesses the bulk properties of water. Continuum approaches involve approximating the
solvation free energy by assuming that it can be decomposed into "electrostatic" and "non-
electrostatic" terms:
AGsolr = AGelec + AGnp (9)
Where AGsolv is the solvation free energy, and where AGelec and AG refer to the electrostatic
and non-electrostatic components respectively.
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a) The non-electrostatic term, AG
This term is assumed to result from van der Waals interactions between solvent and
solute combined with the unfavourable cost of disturbing the bulk water environment.
Within AMBER, AGnp is taken to be proportional to the total solvent accessible surface
area (SA) of the molecule, with a constant of proportionality that is derived
experimentally1 .
b) The electrostatic term, AGelec
The electrostatic component of the solvation free energy is obtained from the difference
in electrostatic potential between the solvated and de-solvated forms:
AG^=yS«,(fWr,)-(«C(ri)) ("»^ i
Where <f)so] and <j>yac refer to the electrostatic potential of solvated and gas-phase atomic
partial charges, qt, for a position vector r. Partial charges in the interior of the molecule
are assigned a dielectric constant of 1, and those that are solvent exposed assigned a value
equal to that ofwater.
The electrostatic potential can be solved to arbitrary accuracy by numerically solving the
Poisson-Boltzmann (PB) equation14. Whilst accurate, this numerical method is
computationally very expensive and instead, a fast, analytical generalized Born15"19 (GB)
approximation to the PB equation is often used:
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The term ry refers to the distance between atoms i and j, and the term R refers to the Born
Radius, a measure of the degree to which an ion is buried in the molecular interior. Thus, deeply
buried atoms have large effective radii, whilst those closer to the exterior have small radii. In the
limit of complete solvation, the Bom Radius reduces to the van der Waals radius.
The function fGB varies in accordance with the Bom radius and inter-atomic distance as follows1:
fc ~r}gb r + RtR exp( My ' J ARM/ (13)> j
In summary the GB approximation is significant for three reasons:
1. It increases the rate of phase space sampling because the viscosity of water is not
considered.
2. The rate of simulation is accelerated because explicit water interactions are ignored.
3. Good agreement has often been observed between GB and explicitly solvated and
experimental models19"23.
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One downside of the GB approximation is that it does not implicitly consider hydrogen bonding.
Thus, in systems where hydrogen bonding dominates there is a danger that the GB model fails to
represent adequately the non-electrostatic solvation term. In this thesis the GB model is reserved
for rational structure prediction, where rapid phase space sampling is given higher priority than
accurately modelling each visited state.
3.4. Molecular Dynamics (MD) simulations
Equation 8 sets out an approximation for the interaction energy of the molecular system. It is
frequently useful however, to know how these interactions direct the time evolution of the
system.
3.4.1. Newton's equation of motion24
The differential of the potential energy function with respect to the parameters (coordinates,
bond angle, dihedral angle) determines the force acting on the system in any given configuration.





In which a particle i, ofmass m, moves under a force F in the x direction.
Equation 8 describes a coupled system in which changing the position of one atom effects the
interactions experienced by each of the other atoms. Coupled systems of this nature cannot be
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solved with standard analytical techniques and the modeller is forced (instead) to resort to finite
difference techniques.
In the finite difference approach, the integration process is split into a number of small stages,
each of which is separated in time by a fixed quantity, St. Knowledge of the positions and
velocities of a particle at a time / allows a subsequent set of positions and velocities to be
established at a time (t + St). Forcefield software assumes that the acceleration, velocity and
positions of the particles in the system can be approximated using a Taylor series expansion24:
r(/ + 5t) - r(/) + Stx{t) +—St2a(t)+—#3b(/) + ... (15)
2 6
\(t + St) = v(/) + $a(/)+—$2b(0+—#3c(f) + ... (16)
a (/ + Si) = a(/) + Stb(t) +—St2c(t) +... (17)
b(t + St) = b(t) + Stc(t) + ... (18)
In the equations above, v refers to velocity, t to time, a to the first derivative (acceleration) and b
to the second derivative (the rate of change of acceleration). Thus the velocity and position of a
particle at a time frame (/+c>/) can be calculated from the position of that same particle at the
previous time (/). The integral is solved within AMBER using the velocity Verlet integration
algorithm1.
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The potential energy surface that arises from the particle in the new position (t+dt) permits a
new set of forces to be calculated for the system. Repeated cycles of force evaluation followed
by integration allow a number of time dependent trajectories to be simulated for the system.
3.4.2. Temperature regulation
There are two approaches applied in this research to the problem of temperature regulation. The
first is the Langevin25"27 dynamics approach in which adjustments to temperature are based on
randomized collisions with imaginary solvent particles. The second is the Berendsen algorithm28,
in which the system is coupled to an imaginary heat bath.
a) Langevin dynamics25"27
In the Langevin model the force acting on a given particle is assumed to arise from
three sources; interactions with other particles (via the normal force-field equation),
friction (arising from solvent viscosity) and random collisions with surrounding
solvent particles. The Langevin equation therefore expresses the relationship
between these competing forces as follows;
M,^^ = F,{*,(/)}-F/h'{xi(0} + R,(0 (19)
Where / denotes a partcle of mass m and position x at time t. The term F is the force
arising from the normal force-field equation, the term Fr"c is the Frictional
component:
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at
(20)
In which /is the collision frequency26 and the term R, the random collision
component. The Langevin equation within AMBER is integrated with a simple leap¬
frog strategy27.
The Berendsen thermostat28
The Berendsen thermostat regulates temperature by periodically rescaling the
velocities of the particles within the system so that the average temperature over
many time steps is pushed towards a "target" temperature. Thus, during each
iteration of the Berendsen algorithm, the "new" velocities, vnew, are equal to the
factor-modified "old" velocities, v°'d, as follows:
Where X is a scaling factor based on the difference between the "actual" (T(tJ) and
"desired" (T0) temperature of the system, as well as the extent of coupling to an
imaginary heat bath (/a). Thus,
In which At refers to the integration time step. The smaller /a is, the tighter is the
coupling to the heat bath.
v," = Xv°'d (21)
(22)
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The temperature of the system is calculated directly from the kinetic energy of the
system as follows:
(23)
Where D is the number of degrees of freedom and kB is the Boltzmann constant.
c) Which temperature regulator is best?
The Berendsen thermostat, due to its simplistic velocity rescaling procedure, relies
on atomic collisions to equilibrate velocity within the simulation box. This has the
disadvantage that "hot-spots" can occur in isolated areas, particularly with explicit
solvent simulations. The random collisional component of the Langevin method
prevents the occurrence of these "hot-spots" and is thus the preferred temperature
method for explicit solvent simulations.
3.5. Energy minimization
It is frequently necessary to find a local minimum in configuration space in algorithms such as
"Basin Hopping" (Section 3.6.2), or when generating initial structures from which to begin MD
simulations. The challenge with minimization is to find a set of coordinates that satisfy the
condition:
dE _/(* +&)- f(x) _ Q (24)
dx,
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3.5.1. Steepest descent
The steepest descent method is an iterative process in which the positions of the atoms in the
system are progressively altered until a minimum is found. The updated atomic positions are
obtained during each iteration through a vector translation Sk as follows:
S*=TT (25)g*
Where gk represents the potential energy gradient.
Each new Sk vector specifies a direction perpendicular to the previous vector, and whilst this is
beneficial for initial minimization, the algorithm is inefficient for many cycles.
Once a direction in which to move the particles in the system has been established, it is then
necessary to consider how far in this direction the system should go. This is typically done by a
line search or an arbitrary step approach.
3.5.2. Conjugate gradient descent
The conjugate gradient descent algorithm is computed as follows:
v*+i=-g*+VA- (26)
Where \k+J refers to the new direction in which to adjust the coordinates, X/f is the starting
configuration, gk the potential energy gradient, and vk the previous conjugate gradient direction.
The function thus gives rise to a direction vector that is weighted to the previous vector by a
constant of proportionality.
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3.5.3. Which method is best?
The steepest descent method is often employed during the first few cycles of minimization
because it can descend high energy 'hills' more rapidly than a conjugate gradient method.
Following this "initial" minimization, the conjugate gradient method is often used because it
avoids inefficient "zig-zagging".
3.6. Conformational sampling
Chapter Four and Chapter Five deal with rational structure prediction. This section outlines some
of the existing structure prediction methods used in this research.
3.6.1. Simulated Annealing (SA)29
The principle of simulated annealing is this:
1. Begin with a molecule in a given configuration. Simulate the dynamics of the
molecule at a high temperature (often ~ 800-2000K) for a given period of time.
2. Progressively cool the molecule to OK.
3. Obtain an output structure and use this as a starting structure for step 1.
4. Repeat steps 1-3 for a given number of cycles.
At high temperatures, the molecule is presumed to sample a large potential energy surface. As
the molecule cools it begins to assume a shape that reflects an increasingly restricted potential
energy landscape. At the final temperature (0 K) the molecule is presumed to have collapsed into
a structure that corresponds to a minimum energy pocket. It is hoped that this energy pocket
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corresponds to (or lies close to) a global energy minimum for the system that maps to a
biologically meaningful three-dimensional structure.
3.6.2. Basin Hopping (BH)30"34
The principle of BH is similar to that of a traditional Monte Carlo (MC)54 algorithm in the sense
that changes to configuration space occur randomly, abruptly and in a time independent manner.
However, a key difference with the BH model is that the potential energy space is reconfigured
to a transformed energy landscape in which the energy value, E, at each point in configuration
space, X, is set to the value for the minimized structure starting from that point30. This
transformed energy can be described succinctly as30:
E(X) = min{£(x)} (27)
Where "min" refers to the minimized energy starting from the configuration X.
Thus the "transformation" converts an initial bumpy and undulating landscape into a set of
"square" energy minima (Figure 3.7.2.1).
Transitions in configuration space are then attempted using a metropolis-type criterion within the
framework of the transformed surface with the advantage that high energy states are less
penalised by Boltzmann weighting than ordinary MC attempts (Figure 3.7.2.2).
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Figure 3.7.2.1 A schematic representation of the transformed Energy surface (dotted line)
shown in comparison to the non-transformed surface (solid line).Adapted from Wales 0
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3.6.3. Replica Exchange (RE)
One pitfall of conventional MD and MC methods is that configurations often become trapped in
local regions of PE space. Such drawbacks are inherent to canonical ensemble simulations
because each state exists only in relation to an energy dependent Boltzmann distribution. In a
Replica Exchange (RE) Simulation, a number of simulations are performed concurrently at
different target temperatures35"18. After a specified number of MD steps, each simulation is
afforded the opportunity of swapping its atomic configuration with that of a neighbouring
simulation with a probability determined by a metropolis-type function. Configurations that
would otherwise be trapped within a local energy pocket are thus given the opportunity to
perform a random walk to a new and unexplored region of PE space.
a) RE theory35
An RE system consists of M non-interacting copies (or replicas) at M-different
temperatures (Tm) within a canonical ensemble. Each state, X, (describing all the replicas
at any given moment) can be thought of in terms of the coordinates (q) and momenta (p)
of each of the associated replicas. Mathematically X can be stated as:
x„ = (wa) (' = I"*'") (28)
Where the subscript i refers to the /th replica (ofM possible replica states) and the value n
refers to the «th state, x.
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b) Describing the RE system35 38
Each replica within every state X exists in isolation. Accordingly, the weight required to
specify succinctly each state is merely the product of individual Boltzmann factors
associated with each of the M replicas.
The weight factor for each state X is:
Where kB refers to the Boltzmann factor and H refers to the Hamiltonian for the kinetic
and potential energy terms of the system for a configuration q and set ofmomentap.
In the instance of an exchange event, a pair of replicas within a state X swap their
coordinate configurations. The momenta associated with the swap must be rescaled to suit
the new temperature environment. The procedure is demonstrated in the following simple
example.
Consider two replicas with the following attributes:
(29)
Replica 1: R{ = (ql,pl) (T = 300 K)
Replica 7: R2=(q,,p2) (T = 250 K)
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In the event of an exchange, replica RI adopts the configuration of replica R: and replica
R2 adopts the configuration of replica Rh The momenta information associated with each
configuration is then be rescaled as follows:
Replica I: P"'" = ' IF (30)
Replica 2: T=J^*P, (3D
Where P"mrefers to replica 1 that has adopted the scaled momenta associated with
replica 2 (P2) and where PP" refers to replica 2 that has adopted the scaled momenta
associated with replica 1 (P{).
After the momenta reassignments each replica exists in terms of contributions from both the
coordinates and momenta as follows:
Replica 1: R{ = (^J^XP2) (32)
Replica2: R2 =(ql>J^xPi) (33)
c) Determining the exchange probability
The transition probability a, , for an exchange between 2 replicas in a state X is
determined in relation to the X weighting factor. The probability of exchange from a
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state T=300 to a state T=200 must be equal to the exchange probability of the state
T=200 to T=300 and as such the following mathematical condition must be fulfilled0:
rx,a(x^x,) = "i,V*) (34)
In which a, , Refers to a transition probability from a state Xi to a state Xj.(X,->XyJ
Substituting for Wx, the rescaled velocities and the Hamiltonian energy for the system the
following transition condition is obtained35:
(X'"X')
= exp[-{Pj -P,)(£{qt)-E(q}.))} (35)
°(X^X,.)
= exp{-A}
where A = [P} - P,)[E{qt) ~E{qj.))
and Where P, —
kbt,
This transition condition (a) can be satisfied with the Metropolis criterion:
a(x,-x,) = 1 (for A<0)
a(x,^x;) = exP {_A1 (for A > 0 )
55
Chapter Three - General Methodology
The transition criterion describes an exchange probability that decays exponentially with
increasing temperature disparity. Exchanges are therefore most likely to occur between
states that are immediately adjacent in temperature space. The temperature of each
simulation must be chosen carefully; too great a difference will result in limited
exchange events, whilst too small a difference will result in exchange between
configurations trapped in the same region of space.
d) Concluding remarks
RE simulations are particularly suitable for parallelised computer runs because each
replica can be simulated by an individual processor^. Thus given a parallel system, the
rate at which a given PE surface can be sampled is increased by a factor proportional to
the number of processors in use. Many standard MD and MC techniques are difficult to
parallelise because simulation setup requires clumsy information flow between
computing nodes (for which information assimilation and exchange is frequently a
limiting performance factor.) RE is therefore a methodology that provides for both better
and faster sampling than the traditional MD and MC methodologies.
3.7. Free energies of binding
Chapter Seven deals with molecular docking of (3-defensins with candidate binding partners.
This section accordingly outlines the methodology for computing the binding-free energy of
docked structures. The method of choice is that of the approximate MM-PBSA approach
developed by Kollman et al. in 2000j9, and implemented in AMBER 9.
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3.7.1. The MM-PBSA method39
The MM-PBSA method, whilst prone (in principle) to error has in practice produced good
agreement with experiment, particularly with regards to binding free energies40"49. For example,
Kollman et al. report that the MM-PBSA method accurately predicts the absolute binding free
energy of an HIV reverse transcriptase inhibitor, T1BO, with calculated values of-13.2 kcal/mol,
versus -11.6 kcal/mol for the experimental procedure42.
With the MM-PBSA approach, a typical MD simulation is first run with the full set of MD
ingredients; explicit solvation, counter ions and periodic boundary conditions. A set of
representative snapshots of the molecular trajectory are then extracted and each molecule of the
snapshot stripped of surrounding water molecules and counter-ions. The free energy of each
trajectory is then approximated with a Poisson-Boltzmann surface area50 term that replaces the
explicit water as follows:
G = EMM + G PBSA — TSmm (36)
Where G is the calculated average free energy and where Emm is the average molecular
mechanical energy:
EMM — Ebond T E angle T Etors T Evdw T E elec (3 V)
(The subscript terms on the right hand side refer to bond, angle, torsional, van der Waals and
electrostatic terms respectively51)
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Gpbsa refers to the free energy of solvation, which can itself be split into two terms:
Gpbsa = G PB + GNP (38)
Where GPB is the electrostatic contribution to the solvation free energy52, obtained through a
numerical solution of the Poisson-Boltzmann (PB) equation, and where GNP is the non-polar
contribution, proportional to the solvent-exposed surface area52'53. The term Smi refers to the
solute entropy which, in AMBER 9, is obtained with normal mode analysis51.
3.7.2. Calculating binding free energies
The free energy of association of two molecules, A and B, can now be expressed as follows:
Where A and B refer to the free species, and AB to the bound species.
A thermodynamic cycle (Figure 3.7.2.1) of the process relates this simple expression to the
molecular mechanical properties of the system as follows42:
A + B -> AB (39)
A + B —AG°Mms > AB
aqu aqu
^-AG"oh,
Am + V AB
Where,
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~ ^Hgas ~ TAS — AGpbsa — AGpbsa






AAGsa = AG£ - (AG^ + AGsJ (43)
Thus, a variety of docking attempts are made (each in a different orientation) with two
molecules, A and B, using a variety of MD based sampling strategies (discussed in Chapter
Seven). The MM-PBSA approach is then used to rank the "quality" of these docked structures
via a comparison of relative free energies of binding. In addition to this, absolute binding
energies for a selection of defensins are also calculated so that the binding efficiency ofHBD1, 2
and 3 can be ranked.
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Chapter Four
Rational Structure Prediction with Static Disulphide
Bridges
4.1. Introduction
This Chapter and Chapter five deal with techniques for rationally predicting the structure of
defensins. Methodologies that invoke a static disulphide description are considered in this
Section, whilst those involving mobile-disulphide descriptions are discussed in Chapter Five (the
need for a mobile disulphide procedure is discussed in due course).
4.1.1. The protein folding problem
Levinthal in 1968 showed that a random global minimum search within a small biological
system possessing just two degrees of freedom per residue would require a folding time scale
greater than the known age of the universe1. His simple observation demonstrated that biological
folding does not involve a random search. Later work provided evidence for the existence of a
folding funnel2"5 in which partially folded6'7 (or nucleated) intermediates arise at various folding
stages. A growing repertoire of algorithms have been (and are being) developed for solving this
problem1'8"22. This Chapter discusses the implementation of some popular folding techniques to
the defensin class of problem: simulated annealing (SA)21"45, replica exchange (RE)20'41,46"91 and
Basin Hopping (BH)3'9"19, as well as some novel folding methodologies.
4.1.2. Interpreting pictorial representations of defensins
Defensin illustrations in this thesis are provided in a cartoon format in which disulphide bridges
are (for clarity purposes) not shown. It is, however, important to realize that disulphide bridges
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are present and that their existence kinetically traps the peptide backbone into specific loops and
secondary structural folds (Figure 4.1.2.1). Discussions of defensin structure in both this Chapter
and Chapter Five often refer to the torsional angles of these loop residues, and hence, indirectly
refer to the disulphide bridges that make these tight turns energetically possible.
and
4.2. System set-up
There are three central facets to the rational structure prediction problem. The first is the
problem of assigning the amino acid charges within the polypeptide; which amino acids possess
what charge during which conformations? The second problem (which is of particular relevance
to cross-bridged species like defensins) lies in the choice of starting structure; what is the best
"initial" configuration from which to begin the folding process? The third and final problem
rests with how to measure the "fitness" of a rationally folded structure - A strict force-field
energy comparison (with its inherent approximations) can sometimes be an imperfect means of
measuring structural fitness.
Figure 4.1.2.1. A cartoon representation of HBD3 showing characteristic a-helix, fi-sheets
disulphide bridge cross-links (shown in blue liquorices format).
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4.2.1. Charge assignment
The issue of charge assignment is contentious in the field of protein folding. Predicting the local
chemical environment of an amino acid, and hence predicting its likely charge state remains an
open problem. Nevertheless, methods do exist for approximating protonation states within a
variety of systems. Case et al for example, detail a "constant pFT' method in which the
polypeptide is subjected to Generalized Bom solvated MD followed by periodic Metropolis
Monte Carlo transitions in protonation state92"95. The sampling methodology permits the
transition free energy (for a given change in protonation state) to be calculated during a variety
of conformations, and hence the pKa of the selected amino acid estimated92,93. Figure 4.2.1.1
and Figure 4.2.1.2 summarise the predicted protonation states and corresponding protonation
assignments for HBD1, HBD2 and HBD3.
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Figure 4.2.1.1. The charge assignments for the protonation sites within HBD1, HBD2 and
HBD3. ARG is not supported by the constant pH algorithm, and it is accordingly assigned a
positive charge owing to large resonance stabilisation of the proton-absent form. The protein
backbone is shown as a thick, black line. Charge assignments ("+" or are denoted on the
1 letter amino acid code.
HBD1 (+6)
+ + + + +
ID 2H 22K 29R 31K 33K 36K
NH3+ COO-
HBD2 (+7)
+ + + + + + +
6K 12H 18R19R21K 32K 35K 36K
NH3+^COO-
HBD3 (+11)
4- + + + + +++ + +4.+
8K 12R 14R 17R 26K 27E 28E 32K 36R 38R 39K 42R 44K 43R 45K
NH3+ COO-
4.2.2. Generating initial geometries
The rational structure prediction algorithms outlined below (unless otherwise stated) employ the
following procedure for generating initial structures:
1. A protein sequence is read into the xleap component of AMBER using the
"sequence" command. This process introduces a default set of fTsheet angles to the
entire sequence with the result that the side chains alternate above and below the
plane of the backbone.
2. Disulphide bridges within the sequence defined in (1) are bonded in their canonical
form. This results in bonds that are widely displaced from their equilibrium value,
sometimes by as much as 30 Angstroms.
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3. The structure in step (2) is minimized with sander using the standard minimization
settings (Section 4.9). This results in a compact structure in which the disulphide
groups are connected at their equilibrium distance.
There are some obvious drawbacks with generating preliminary structures in this fashion, the
most obvious being that conformational freedom is reduced. The problem of disulphide bridges
and how to deal with them is a recurring theme (and central problem) of this research and is
considered in greater depth in the proceeding Chapter.
4.2.3. Fitness criterion
Unless otherwise stated all fitness measurements encompass an energetic and torsional
comparison with the target structure*. The torsional component is obtained with a harmonic-type
energy function for sequence stretches that are expected to exhibit secondary structure in the
natively folded state. The total "fitness", Efitness, is then determined as follows:
^'fitness ^folded ' ^tor
Where Efolded is the unbiased single point energy of the rationally folded molecule, and where Eror
refers to the torsional bias term:
= (2)
i
The torsional weighting is used because an unbiased energy comparison in some cases fails to
distinguish native from non-native structures. Accordingly, the penalty term better separates "good"
structures from "bad" structures.
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Where K refers to a constant, (p to the torsional angle for amino acid / and (p'q to the
eq
corresponding native state torsional value (Figure 4.2.3.1).
Figure 4.2.3.1. The unbiased energy (black) versus the torsionally penalized energy (red).
Structure Index
4.3. Simulated Annealing (SA)
SA is historically an early folding strategy36 and one that has enjoyed success with small systems
such as met-enkephalin4<) and fragments of BPTI41. However, a dearth of literature publications
for systems larger than 20 residues indicates that this is the upper limit of this strategy. Does this
limit hold when the peptide in question is conformationally restricted (as is the case with
defensins)? Do such restrictions to the potential energy surface make the sampling problem
tractable9
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4.3.1. Method
MD simulated annealing is applied to initial model constructs as described in Chapter Three
using standard settings (Section 4.9). The SA protocol is implemented with a combination of
Fortran 90 and cshell (Figure 4.3.1.1).












Set input structure = output structure
Final Output Structure
4.3.2. Results and discussion
The standard fitness criterion reveals that SA (applied as a standalone procedure) does not find
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reveals significant divergence from the experimental native NMR species (.Figure 4.3.2.1.)
Furthermore, many of the required phi-psi angles are never sampled during the simulation
{Figure 4.3.2.2.), an observation that lends credence to the notion that a restricted
conformational space (contrary to initial hopes) inhibits rather than aids sampling. Indeed, key
residues such as VAL 14 within HBD2 never sample the required torsional space {Figure 4.3.2.3
and Figure 4.3.2.4). A likely explanation for this is that the loop regions of the molecule remain
kinetically trapped by the disulphide cross-linkages in the starting configuration, such that
escape to a global (or less frustrated) minimum is kinetically impossible, even at very high
temperatures.
Work presented elsewhere in this Chapter (and additionally in Chapter Five) attempts to deal
with the problem of kinetic trapping.
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Figure 4.3.2.1. Simulated annealing energies (black) versus 20 minimized native NMR
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Figure 4.3.2.2. Simulated annealing structures shown in "cartoon" mode for the fittest
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Figure 4.3.2.3. Scatter plots of torsional angles for each of the final SA structures (left)
compared to 20 native NMR structures (right) for each of HBD1-3.
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Figure 4.3.2.4. A: Phi and Psi angles for residue 14 (Valine) of HBD2 for both simulated
annealing and native NMR structures. B: SA torsional structures shown schematically for a
variety of other residues (NMR is shown in red and SA in black). The absence of sampling in the
required torsional space in both cases suggests the existence of kinetic trapping. This problem is
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4.4. MD with altered Hamiltonian states
A central problem with rational structure prediction is the oft inadequate sampling of phase
space. Indeed the complexity of the defensin problem appears to be related (in part) to the
inability of algorithms to address the kinetic trapping problem. In this section a methodology is
outlined for increasing phase space sampling by progressively and artificially "flattening" the
potential energy landscape.
4.4.1. Method
With this strategy the system Hamiltonian is modified so that the PE surface is effectively
flattened. This is done by zeroing the disulphide bridge and dihedral force constants and by
truncating the non-bonded cut off at 4 Angstroms. The disulphide bonding and dihedral twisting
terms are therefore present in the Hamiltonian description of the molecule only in name, for they
provide no energetic penalty to deviations from the equilibrium position. From this vantage point
a burst phase of MD (as it will hereon be referred to) commences in which the molecule is
permitted to sample the flattened landscape in a comparatively uninhibited manner. Following
this initial burst, a set of linear and non-linear transformations restore the Hamiltonian to its
original state (Figure 4.4.1.1 and Figure 4.4.1.2).
The non-linear disulphide bridge transformation is applied iteratively as follows:
F'-" ~ exp[£/> + C] (3)
Where F,„ refers to the force constant to be used in the Hamiltonian description for atom pair i
during iteration n. K and C are constants that are chosen to produce an intuitively desirable rate
of restoration and F° refers to the final intended force constant.
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Figure 4.4.1.1 An illustration of the modifications that flatten energy landscape during the
"burst" phase. The Sections highlighted in red are the components of the force field that are
affected; non-bonded interactions are truncated at 4 angstroms and dihedral force constants
and disulphide bond force constants are set to zero. These modifications are subsequently












Figure 4.4.1.2. A schematic representation ofmodified Hamiltonian sampling simulation.
Input Structure
I
Flatten Hamiltonian for system
I
► Perform burst phase MDfor random time period
I
Linearly restore non-bonded interactions
Repeatfor n cycles ^
Linearly restore dihedral force constants
I
Non-linearly restore dihedral force constants
I
Set input structure = output structure
Final Output Structure
76
Chapter Four - Rational Structure Prediction with Static Disulphide Bridges
4.4.2. Results and discussion
The modified Hamiltonian method, should, in principle avoid the problem of kinetic trapping
associated with the SA procedure. This is not born out in practice. In fact, the energetic
discrepancy (Figure 4.4.2.1) and extent of torsional sampling (Figure 4.4.2.3 and Figure 4.4.2.4)
appear to resemble that obtained via SA. However, despite this apparent similarity, some a-
helical structure is observed in HBD3, and a good "general" topology can be visually discerned
CFigure 4.4.2.2).
It is not clear why this method has failed to produce more effective sampling. One possibility is
that the non-linear restoration phase results in structural collapse that is too rapid for desirable
secondary structural elements to form. Indeed, intermolecular bonds are approximated with a
harmonic potential for which small changes in the magnitude of force constant produce an
exponential change in energy. Future improvements to the procedure will focus on defining
inter-disulphide constraints with a linear energy penalty so that structural collapse can be
generated more gradually.
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Figure 4.4.2.1. the Fitness measure for the modified Hamiltonian technique (black) versus 20
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Figure 4.4.2.2. Fittest structures for each of HBD1-3. Cartoon representations of each defensin
show no discernible secondary structural motif, except for HBD3, which shows desirable a-
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Figure 4.4.2.3. A scatter plot of torsional angles for each of HBD1-3 for both the modified
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Figure 4.4.2.4. A: Torsional scatter plot for HBD2 residue VAL 14 (shown in black) against a
schematic representation of residue VAL 14 in 20 NMR structures (shown as a red blob). B:
Torsional sampling for SA calculated structures for the same residue. The absence of required
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4.5. Basin Hopping (BH)
The BH strategy has enjoyed significant success with cluster problems, which, despite being
governed by a multiple funnel topography, are nevertheless tractable with this algorithm10"1416"18.
Biological folding problems have also been tackled with this algorithm within a coarse grain
force-field framework9 with some success. The BH procedure is attractive in the context of the
defensin problem because the "transformed" PES permits (in principle) efficient reorganisation
of disulphide-bridge-loop-regions.
4.5.1. Method
Burst phase dynamics are performed with the sander component of AMBER and BH runs are
performed with GMIN version 2.2.31. Where necessary, cshell scripting in conjunction with the
AMBER module ptraj are used to interconvert AMBER and GMIN formats.
A central problem with the basin hopping task rests with the choice of parameters; with more
than 30 continuous variables, what is the most suitable choice? This optimisation problem is
outside the scope of this research and, as such, only the temp and step parameters are optimised.
The remaining parameters are chosen on the basis of their empirical success with other systems9.
Optimisation is achieved with the small, 20 amino acid test-system test of trp-cage as follows;
a) Optimising temp and step
The temp and step parameters are optimised by systematically changing the selected
variable whilst holding the remaining variables fixed. Each stepwise change in
magnitude is followed by a BH run of 3000 steps and the "fitness" of the parameter
choice assessed by tabulating the energetic output (.Figure 4.5.1.1 and 4.5.1.2).
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Figure 4.5.1.1. Relative energies of the lowest minimum obtained using different step sizes. A

























Figure 4.5.1.2. Relative energies of the lowest energy minima obtained from different
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b) Choosing the number of BH iterations
The BH algorithm, during the first one thousand (or more) iterations, generates rapid
structural collapse. Following this initial event subsequent cycles appear only to
generate local sampling. Employing 3000 - 4000 BH cycles produces structures that are
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not significantly lower in energy (or different in structure) to those obtained with 20 000
cycles.
Figure 4.5.1.3. RMS deviation of BH calculated Trp-cage structures compared to that of the
NMR derived structure96.Rapid initial collapse is followed by non-productive local sampling.
12-
The strategy in this research focuses on combining aspects of the BH directed structural collapse
with traditional MD in order to optimise both global and local sampling (Figure 4.5.1.4) as
follows:
1. A "burst phase" ofMD (as outlined in Section 4.3.) is used to sample phase space
in the non-bonded state.
2. BH is invoked (for 2000 to 5000 steps) with the canonical disulphide bridge
connectivity to direct global collapse.
3. A briefMD equilibration is performed to permit local kinetic sampling.
4. A thorough minimization is performed to locate the closest minimum.
Dd
0 2000 4000 6000 8000 10000
Number of BH cycles
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Apply BH (2000-5000 steps)
I
Repeatfor n cycles Extract 3 lowest energy structures
MD at temperature T (all 3 structures)
I
Final Minimization (all 3 structures)
I
Choose 1 ofthe 3 structures
Final Output Structure
4.5.2. Results and discussion
BH as a standalone procedure has enjoyed significant success with a variety of systems but no
such success is observed here with the defensin family of proteins. Indeed, rapid structural
collapse occurs, but the rearrangements required for the formation of native structure do not
(results not shown). Why is this? The most intuitive explanation is that folding requires
kinetically trapped loop regions to be re-arranged into "more native" structures during the
folding process. In many cases, this event (or these events) would require between 6 and 12
amino acids moving in unison and (possibly) passing through one another. The probability of
GMIN version 2.2.1 used in this research encounters significant problems when performing torsional
variations to N-terminal proline. As such, there are no publishable results for HBD2 (which contains an N-
terminal proline).
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such enormous cooperative movement occurring as a result of random changes to randomly
selected torsional angles is exceedingly small. Thus, BH as a standalone procedure does not
appear to be effective in solving disulphide-cross-linked systems of this ilk. Furthermore, it
remains a distinct possibility that the BH parameter set is not appropriately optimised. GMIN
versions 2.2.1 and higher allow for cooperative changes to selected residues, and more
productive sampling might be obtained with appropriate changes in the nature (and magnitude)
of this cooperative change.
The hybrid BH-MD method aims to circumvent the problem of local trapping by seeding BH
from a variety of distinct and extended geometries. The benefits and pitfalls of this strategy are
here discussed with reference to HBD3. Whilst the hybrid method fails to generate the intended
secondary structural motifs (Figure 4.5.2.1 and Figure 4.5.2.2), it nevertheless avoids the
trapping problem observed with both the SA and modified Hamiltonian approach. For example,
the residue CYS 23 within HBD3 samples the correct torsional space with BH-MD but remains
kinetically trapped in the case of SA {Figure 4.5.2.3). Furthermore, scatter plots of dihedral
sampling reveal that the hybrid method visits more favourable regions of phase space than SA
{Figure 4.5.2.3).
The BH-MD method avoids the problem of kinetic trapping, but alas, it does not locate the
global fold. Why the method fails is not clear. One reason may lie with the assumption that all
disulphide bridges form at the same moment in time. In reality the nucleated structure on which
the global fold ultimately depends may only form within a partially cross-linked complex100. The
effect of dynamically forming and breaking disulphide bonds is considered in greater depth in
Chapter Five.
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Figure 4.5.2.1. The fitness of the BH-MD generated HBD3 structure (black) versus that of 20
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Figure 4.5.2.2. A cartoon representation of the fittest BH-MD generated structure of HBD3. No
native secondary structural motifs are detected.
HBD3
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Figure 4.5.2.3. A. Torsional scatter plot for HBD3 showing the full range of visited dihedral
angles for the BH-MD method (left) in comparison to that of SA (right). The BH-MD method
preferentially samples energetically favourable regions of phase space compared to SA. B. A
torsional scatter plot for the residue CYS 23 for both the BH-MD (left) and SA (right) method.
The torsional regions sampled by the native NMR structures are shown schematically in red and
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4.6. Replica Exchange (re)20'47,48'52"57,59'61'62'64"66'70"75'79"83'85'89'31
Conventional simulation methods within the canonical ensemble are often subject to the pitfall
of local trapping. This problem can often be overcome with generalized ensemble techniques
such as RE in which random walks through PE space are permitted20. Indeed, a variety of
distinct (and otherwise unvisited) conformations can often be observed with re77 79 81 •84-89-90
method has accordingly enjoyed significant success with modelling aggregation problems87 and
protein folding problems20'48'49'53'54'58'59'61'64'75,80,83,89'90. For example, Sanbonmatsu et. al
demonstrate that RE sampling for the system of met-enkaphalin is 5 times more extensive than
with normal constant temperature MD84, a phenomenon that permits helical to non-helical
transitions to be identified.
4.6.1. Method
REMD (as outlined in Chapter Three) is performed using 64 replicas with standard MD settings
{Section 4.9) and Langevin dynamics. The temperature of each replica is assigned on the basis of
the following exponential function:
T, = To exp(Ki) (4)
Where T, refers to the temperature of replica Ta to the initial temperature and K to a constant
(found by trial and error) that is scaled by a factor of /. The temperature spacing is optimised by
examining the exchange rate for stepwise variations in K. RE studies of other systems ordinarily
choose a temperature spacing that gives rise to an acceptance ratio that lies between 0.15 and
0.7520'41'46"91. Accordingly, the parameters in equation 4 are selected so that the acceptance ratio
falls in between these limits {Figure 4.6.1.1). The initial temperature is set to 278 K, and the
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constant, K, chosen to be 0.03 via a trial and error process {Figure 4.6.1.2). All the initial
structures are seeded from a single, xleap generated geometry and exchange attempts are made
every 2ps (Other studies have made use of lower exchange periods49'83, but this system, with a
more extreme temperature range is thought to require a slightly longer equilibration period
between exchange events).
Figure 4.6.1.1. The exchange rate for HBD2 for a 2ns REMD run. The temperature spacing is
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Figure 4.6.1.2. Energy distributions for replicas within HBD2 at different temperatures (K). A:
Temperatures 278 (blue), 287 (red) and 295 (black). B: Temperatures 1683 (blue), 1734 (red),
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4.6.2. Results and discussion
REMD, in principle, allows kinetic barriers to be overcome because replicas are permitted
random walks through potential energy space with every exchange event. However, this
increased sampling does not (in this case) translate to better structures (.Figure 4.6.2.1). Indeed,
only HBD2 exhibits any discernible secondary structure, and even so, only in the form of a
partial N-terminal a-helix.
The observed torsional sampling at first glance looks promising (Figure 4.6.2.2). However, this
apparently extensive sampling is likely to be an artefact of sampling geometries from
conformationally diverse, high energy states. Closer inspection of the dihedral angles of
individually kinetically trapped residues reveals that the correct conformational space for many
key loop residues is never visited. This kinetic trapping quagmire is (again) well illustrated by
the residue VAL 14 ofHBD2 (Figure 4.6.2.3).
This REMD study is very much a preliminary investigation and further optimisation and
experimentation is required. Future work will centre on seeding simulations from a variety of
different starting geometries so that loop regions that are trapped in different regions of potential
energy space can interchange. A more advanced RE procedure for dealing with dynamic bond
formation and breakage is discussed in Chapter Five.
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Figure 4.6.2.1. Cartoon representations of replica exchange generated structures for each of
HBD1-3. The structures are representative and sampled from the temperature of 287 K. HBD2 is





Figure 4.6.2.2. Torsional scatter plots for HBD2. A: All residues for REMD HBD2 (left) v.v SA
(right). B: The residue VAL 14 shown with a schematic representation of the native NMR
sampled dihedral space. The absence ofsampling in the required region shows that REMD fails
to relieve kinetic trapping.
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4.7. Backbone mapping
Genetic and bioinformatic studies indicate that defensins are likely to have evolved from a single
ancestor97"99. Divergent evolution from this molecular godfather is presumed to have produced
the overwhelming diversity of defensins that are now ubiquitous to the animal and plant
kingdoms99. Defensins, whilst dissimilar in sequence, tend to exhibit similar folds to one
another, especially with regards to the various loop regions and bends that intersperse the
various secondary structural elements. How much of the relative ancestral fold is maintained
across the defensin family?
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This Section investigates the outcome of superimposing the structure of related and unrelated
defensins onto one another. Can HBD1 be folded by mapping it onto the backbone of HBD2? If
not, is the resulting structure at least a better geometry from which to begin the folding process?
4.7.1. Method
The mapping procedure is implemented as follows:
1. The pdb file of each of the template structures is cleaved so that only the backbone
atoms remain, and often a single atom within the side chain.
2. The modified pdb file from step (1) is loaded into xleap using the
"loadpdbusingseq" command (see Section 4.9 for command details). This permits a
least squares fit of the sequence of interest onto the template pdb coordinates.
3. The structure from step (2) is minimized with standard settings in a wholly non-
bonded form.
4. The disulphide absent form of the structure in step (3) is canonically bonded within
xleap and re-minimized with sander.
The resulting structure is heated from OK to 300K and Ins of implicitly solvated production MD
is performed with standard MD settings (Section 4.9).
With this procedure HBD1 is superimposed onto HBD2, MBD7 and the murine orthologue,
MBD81 (Figure 4.7.1.1). HBD3 in turn is superimposed onto its murine orthologue, DEFB14
(.Figure 4.7.1.2).
1 Defensins are often named with conflicting nomenclature. Murine [3-defensins, for example, are
sometimes given the abbreviation MBD, and at other times given a DEFB prefix.
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Figure 4.7.1.1. The backbone mapping sequence alignment for HBD1 superimposed onto













































































































































Figure 4.7.1.2. The backbone mapping sequence alignment for DEFB14 superimposed onto



















































4.7.2. Results and discussion
The method of backbone superposition yields some surprising results. The structure of DEFB14
for example (Table 4.7.2.1. and Figure 4.7.2.2) produces the expected native folds (although this
cannot be confirmed until an experimental DEFB14 structure is published). In some respects this
result is unsurprising for the system of DEFB14 because the two molecules share a sequence
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similarity of approximately 75%. Superpositions of HBD1 onto HBD2, MBD7 and MBD8
produce less favourable results, although in some cases partially formed (3-sheets and a-helices
are observed {Table 4.7.2.1. and Figure 4.7.2.2-5). For each of these HBD1 superpositions the
secondary structures are not located in the correct regions of the molecule, but, despite this, there
is some evidence for partially correct folds. The residue LYS 10 (for example) exists in a tightly
confined and unusual region of torsional space within the native state. Torsional values for the
superimposed structures ofHBD1 (onto both alignments ofHBD2) are very similar to the native
NMR case {Figure 4.7.2.2). This observation provides support for the notion that backbone
superposition (at least in the case of a reasonably related protein) provides a better starting
configuration than a randomly chosen geometry. This may be of particular benefit because the
mapping procedure (without extensive MD equilibration) is brief and capable of generating
starting structures within a matter of minutes.
Table 4.7.2.1. All atom RMS deviations (in Angstroms) for superpositions of HBD1.
Alignment RMS/Angstroms
HBD1 on HBD2 (1) 8.31
HBD1 on HBD2 (2) 9.09
HBD1 on MBD7 10.99
HBD1 on MBD8 10.18
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Figure 4.7.2.2. A Ramachandran plot of torsion angles for HBD1 (A) and HBD3 (B). The red
outlines in both cases denote a schematic range of values present within the solved native NMR
structures. A) Superpositions involving each of HBD2 (both alignments), MBD7 and MBD8 are
shown alongside the torsional angle of GLY 10 within a randomly generated xleap geometry
(shown in blue). B) Torsional angles for residue CYS 23 within HBD3 and the superimposed
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Figure 4.7.2.2. The backbone mapping structure of DEFB14 superimposed onto native HBD3.
The cartoon depicts the characteristic a and (5-folds. There is unfortunately no experimental
structure to validate this structure.
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Figure 4.7.2.3. The backbone mapping structure of HBD1 superimposed onto native MBD7 (A)
and native MBD8 (B). For each alignment there is some partial secondary structure formation: fi-
sheet structure in alignment A, and a-helical structure in alignment B.
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Figure 4.7.2.4. The backbone mapping structure of HBD1 superimposed onto native HBD2 with
2 alignments (A and B). Alignment B appears to have better secondary structure than A.
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4.7.3. Conclusion
In cases in which the defensin to be folded shares homology with the template molecule, the
mapping procedure is similar in many respects to that of homology modelling. Indeed,
homology modelling requires that regions of like sequence share like structure. Rationally folded
DEFB14 unsurprisingly possesses similar characteristics to the published homology model.
Superposition onto structures that share low sequence homology does not give rise to the global
fold. However, it remains a possibility that these partially formed configurations capture at least
some of the "correct" folds and, hence, provide a better in silico starting geometry than an
arbitrary xleap generated configuration.
4.8. Chapter conclusion
The prevailing evidence is that disulphide cross-linkages do not conformationally restrict
defensins in a useful way. On the contrary, they appear to trap the molecule in local, frustrated
minima from which escape to the global minimum is (for all intensive purposes) impossible.
Key to solving the defensin structure prediction problem is a means for knowing when and under
what conditions to break and form disulphide cross-bridges. Chapter Five discusses novel
procedures for achieving this, and draws conclusions about the nature and tractability of this
problem.
4.9. Standard simulation settings
All dynamics and minimizations are run (unless otherwise specified) with the settings in Table
4.9.3. Computer code for implementing PE sampling is written in cshell or FORTRAN (See CD
for code).
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Table 4.9.1. Simulated Annealing Settings
Property Value Explanation
High temperature 800K A high temperature allows the potential
energy space to be explored efficiently.
Low temperature OK Final temperature that traps molecule in
minimum energy pocket. This may or
may not be the global minimum.
Hot MD time 30 ps The length of time that the system is
maintained at the high temperature.
Cool step Non-linear function An exponential cooling step is thought
to provide better sampling than a linear
one.
Table 4.9.2. Standard xleap commands.









bond seq. 13.SG seq.34.SG In this case the "SG" atom
of residue 13 and 34 are
bonded to one another.
Save coordinate and
topology files.
saveamberpann seq seq.parm seq.crd "seq" identifies the molecule
to be saved, "seq.parm"
refers to the topology file (or
Hamiltonian) and "seq.crd"
refers to the coordinate file.
Load pdb file using
existing sequence with
name "seq".
seq = loadpdbusingseq seq.pdb
(NALA ARG ARG CLYS)
This command is often
useful when superimposing
a modified sequence onto a
pre-existing set of
coodinates.
Save pdb file to disk savepdb seq seq.pdb "scq.pdb" refers to the name
of the pdb file to be saved.
Table 4.9.3. Standard MD settings
Parameter Setting Explanation
nstlim 1000 Number of femtoseconds for MD run
igb 0 or 2 Set the implicit solvent environment (0 = gas-phase
simulation) 2 = standard Born solvent simulation.
dt 0.001 or 0.002 Time step for simulation in picoseconds.
ntt 1 (3 when gb=2) ntt=l: Employ constant temperature using weak coupling
algorithm16.
ntt=3: Employ Langevin dynamics.
tempO n/a Specify the target temperature for an MD run. This value
is varied depending on the simulation. For simulated
annealing this is varied from 800K to OK. For standard
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dynamics this is set to 300k.
ntf 2 Ignore contributions from Hydrogen when forming
interaction matrix.
ntc 2 Constrain bonds involving Hydrogen.
Table 4.9.4. Standard Basin Hopping settings
Parameter Setting Explanation
sloppyconv 0.01 RMS convergence criterion for basin hopping
quenches.
tightconv 0.001 Tolerance for the RMS force in the final set of
quenches.
acceptrcitio 0.3 The acceptance ration for the MC exploration of the
transformed surface.
ediff 0.01 Quench minima only considered to be different if
they are ofwithin 0.01 (or less) units of one another.
Updates 100 The number of previous steps saved in the LBFGS
routine.
maxit 250 500 Both integers specify the maximum number of
iterations permitted with the conjugate gradient
quenches. However, the 1st integer (250) applies to
sloppy quench runs where as the 2nd integer (500)
applies to the final quenches.
temperature 20 The temperature at which the MC runs are
conducted.
steps 3000 1.0 The first integer determines the length of the MC
runs. The 2nd integer refers to the chosen annealing
procedure.
step 10 0.4 The 1st integer specifies the maximum step size
(degrees) and the 2nd integer specifies the level of
binding energy tolerance between different atoms.
chpmax 0.4 Charmm keyword. Specifies the maximum allowed
probability for twisting an angle.
chpmirt 0.2 Charmm keyword: The minimum allowed probability
for twisting an angle.
chnmax 10 Charmm keyword: The maximum allowed number of
angles to be twisted.
chnmin 0 Charmm keyword: The minimum allowed
probability for twisting an angle.
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Table 4.9.5. Standard minimization settings
Parameter Setting Explanation
maxcycl 50 000 Maximum number of allowed minimization cycles.
drms 0.005 The convergence criteria determined by the root mean
square force (kcal/mol)
ntpr 1000 Sample energy information every 1000 steps.
ntmin 1 Perform steepest descend minimization for n cycles and
then switch to conjugate gradient descent.
ncvcl 100 Perform steepest descent minimization for 100 cycles.
igb 0 or 1 Default minimization in gas-phase or Born solvent
environment.
Table 4.9.6. Table of constant pH results for HBD1.
HBD1 Fraction Predicted Shift
protonated Pka
AS4 1 0.001 3.708 -3.292
HIP 2 0.232 6.481 -0.519
TYR 3 0.999 9.906 2.906
TYR 14 0.999 10.229 3.229
LYS 22 1.000 10.310 3.310
TYR 28 0.998 9.614 2.614
LYS 31 0.998 9.684 2.684
LYS 33 0.998 9.670 2.670
LYS 36 0.999 9.960 2.960






LYS 6 0.995 9.289 2.289
HIP 12 0.232 6.481 -0.519
TYR 20 0.998 9.774 2.774
LYS 21 0.995 9.269 2.269
LYS 32 0.997 9.588 2.588
LYS 35 0.998 9.691 2.691
LYS 36 1.000 10.356 3.356
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Table 4.9.7. Table of constant pH results for HBD3.
HBD3 Fraction Predicted Shift
protonated Pka
LYS 8 0.997 9.465 2.465
TYR 9 0.993 9.167 2.167
TYR 10 0.978 8.638 1.638
LYS 26 0.999 9.935 2.935
GL4 27 0.000 3.114 -3.886
GL4 28 0.000 n/a n/a
LYS 32 0.972 8.540 1.540
LYS 39 0.990 8.987 1.987
LYS 44 0.997 9.580 2.580
LYS 45 0.999 10.004 3.004
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Chapter Five
Rational Structure Prediction:
Probabilistic Disulphide Bridge Algorithms
5.1. Introduction
Chapter Four provides some evidence for the existence of kinetic trapping within the in
silico folding environment. This Chapter discusses procedures for overcoming this trapping
problem by rearranging the offending disulphide bridges dynamically during MD or BH.
When considering the defensin disulphide bridge problem it is instructive to examine
systems for which folding has been largely characterised. Bovine Pancreatic Trypsin
Inhibitor (BPTI), for example, is a 58 residue, 6 cysteine protein1 known to fold via partially
disulphide-bridged intermediates2"14. The reduced form of the protein is known to adopt a
predominantly denatured configuration13 in which single pair disulphide bridging is observed
for each of the 15 possible pairings14. During this phase, the first, crucial, partially folded
kinetic intermediate, CYS 30-CYS 51 (hereon referred to as 30-51) forms". The second
disulphide bridge, 5-55, can then form by direct, sequential canonical bonding, or via an
alternative (kinetically favoured) set of incorrectly paired states that eventually exchange to
produce the correct pairing15,16. Once these first two canonical pairings have formed (5-55,
30-51), the last remaining cysteine residues (14 and 38)13 are brought together at the surface
of the molecule, and their bonding to one another is then rapid.
In vitro defensin folding requires redox conditions1718, a fact that suggests a BPTI-like,
dynamic-bond folding pathway with many intermediates, and not a two state, nucleation-
condensation mechanism19 23 common to many other small, globular proteins.
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Some key questions raised for the defensin folding problem are thus:
1. At what point during the folding process do canonical connectivity's arise?
2. Do non-canonical connectivity's arise during the folding process? If so, do they
form essential folding intermediate states?
3. At what stage during the folding process can disulphide bridges be regarded as
"glued together"?
4. Do initial folding events partition the potential energy surface in a manner that
directs future productive folding?
These questions cannot be adequately answered with current forcefield methodologies
because the system Hamiltonian in such procedures describes a fixed set of inter-atomic
bonds that do not (and cannot) exchange during the MD process. Indeed, current
simulations of systems such as BPTI invoke single Hamiltonian descriptions of the entire
, 24-26folding process
The challenge, as set out in this chapter, is to develop a procedure that forms and breaks
disulphide bridges with an appropriate criterion.
5.2. Probabilistic bonding method
Each procedure that invokes the mobile disulphide bridge method employs a probabilistic
bonding algorithm that is here discussed.
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5.2.1. Dynamic bond formation and cleavage
The AMBER suite of programs employs a single Hamiltonian operator for establishing the
energy of a system for a given set of coordinates. The challenge for a mobile disulphide
bridge algorithm is thus to:
1. Modify this single Hamiltonian operator so that it can at any time correspond to
a differently bonded (or non-bonded) state.
2. Know when to break and form bonds (and hence know when to modify the
Hamiltonian)
Points 1 and 2 (above) are tackled by generating a priori the entire repertoire of Hamiltonian
states for each of the 8 conceivable canonical bonding connectivities (Table 5.2.1.1.). These
are then toggled between one another with a probability Pab that varies as a non-linear
function of the Euclidean displacement, Dab. between bonded (or potentially bonded) atom
pairs a and b:
In which x, y and z refer to the coordinates of atoms a and b, and where the term Bab is a bias
term that shifts the function along the horizontal axis; it can be interpreted as the distance at
which the probability of bond formation is 0.5. The term Aab determines the rate of change
of probability for a given change in distance and can be regarded in a crude sense as the






over small displacements from the centre point and non-linearly at the "extreme" ends
(.Figure 5.2.1.2).
Equation 1 is applied to snapshots of the coordinates at given intervals (usually 1 - 2
picoseconds) so that the Euclidean distance between bonding pairs can be tracked, and bonds
formed or broken accordingly. Each change in bonding state is mapped to a corresponding
Elamiltonian for the existing set of coordinates and velocities.
Table 5.2.1.1. The conceivable disulphide connectivity's for a typical defensin. The bonding
configuration "1-5", "2-4" and "3-6" refer to the cysteine indexes (beginning from the N-
terminus). The shaded boxes indicate that a bond exists between the specified pair. The
Hamiltonians (H,) corresponding to each connectivity are generated prior to simulation start.
S-S connectivity:
Make a bond?
H, 1-5 2-4 3-6
1 no no no
2 yes no no
3 no yes no
4 no no yes
5 yes yes no
6 no yes yes
7 yes no yes
8 yes yes yes
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Figure 5.2.1.2, Example plots of probabilistic sigmoidal function (Pab) vs Distance. Left: A=
0.8, B = -3. Right: A=2, B--3. Comparison of the two graphs illustrates that the value of A
effects probability gradient.
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The sigmoidal function is chosen because:
1. It is conveniently constrained to values between 0 and 1 and therefore lends itself
well to probabilistic treatment.
2. The function dies off exponentially with increasing displacement in a manner
similar to dipole-dipole interactions.
3. The function contains parameters Aab and Bab that can be optimized for the system
at hand.
5.2.2. Dealing with bonds that "never form"
MD runs frequently give rise to bonding pairs that (if left undisturbed) remain far apart in
Euclidean space for the duration of the simulation. A randomizing term is present in the
algorithm to combat this phenomenon so that bonding can be "forced" upon systems that
would otherwise remain in a non-bonded state. A brief conjugate gradient descent
minimization is performed in order to alleviate non-equilibrium bond-lengths.
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5.2.3. Implementation
The probabilistic bonding paradigm is implemented with an individually compiled Fortran
90 program in which system calls to the AMBER suite of programs are invoked at
appropriate junctures of program flow. In this manner, the Hamiltonians for the system are
generated a priori via the Heap component of AMBER, whilst coordinate and velocity
information are generated with sander. The probabilistic function makes use of the
coordinate and velocity output files following pre-defined trajectory time-lengths and any
changes in bonding state are mapped to the correct Hamiltonian. The overall procedure is
summarized in Figure 5.2.3.1.
"
The "system call" commands exist within Fortran 90 to permit system (and other) software to be run
and terminated within the program flow.
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Figure 5.2.3.1. A schematic representation of the mobile disulphide bridge algorithm. Normal
MD is followed by applying the probabilistic bonding procedure to a snapshot of the
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5.3. Simulated Annealing
5.3.1. Method
The annealing algorithm for the mobile disulphide case is identical to that presented in
Chapter Four, except that:
1. A randomized heating temperature, cool step and heating period are used*.
2. During the heating step a wholly non-bonded Hamiltonian (as opposed to the
canonical one) is employed to permit unhindered sampling of phase space.
3. The mobile disulphide bridge algorithm is applied during the cooling phase.
4. Following the final cooling phase, the canonical Hamiltonian (if it hasn't already
arisen) is invoked for a 30 ps interval prior to final minimization.
The modified SA algorithm is illustrated in Figure 5.3.1.1. The standard settings for the
procedure are summarised in Section 5.7.
"
The extent of this "randomisation" is set in the input tile to lie within a user-defined range.
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Figure 5.3.1.1. A schematic summary of the mobile disulphide bond SA procedure. The
scheme is similar to that of standard SA, except for the heating phase in which the wholly
non-bonded Hamiltonian is invoked, and the last phase, which requires a further 30 ps of
equilibration prior to final minimization.
Repeatfor n cycles
T=T-Fstep
^ Hot MD at temp Twith
no Disulphide bonds
4











5.3.2. Results and discussion
The mobile disulphide bridge SA procedure gives rise to some desirable secondary structural
motifs in the system of HBD2 (Figure 5.3.2.1 and Figure 5.3.2.2), but not in HBD1 or
HBD3 (results not shown). The reason for this failure (and partial success) is not clear.
Indeed, analysis of the torsional sampling for key residues of HBD2 reveals that kinetic
trapping is (to a large extent) circumvented for the residue of VAL 14 (Figure J.5.2.3). It
remains a possibility that the problem lies with the SA procedure, which has not enjoyed
success for systems larger than 20 residues1"7"33. Another possibility is that the procedure
fails to capture vital, non-canonical intermediates. Future work will centre on permitting
non-canonical bonding and (rather than randomising formation and breakage) directing
disulphide pairing in a concerted fashion.
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Figure 5.3.2.1. A mobile bond-SA predicted structure of HBD2. There is some partial
correct (1-sheet formation.
Figure 5.3.2.2. Structural fitness measure of mobile disulphide SA generated HBD2 (black)


























Figure 5.3.2.3. A: Torsional scatter plots of all residues of HBD2 for mobile disulphide
bridge SA (left) and standard SA (right). B: Torsional scatter plots for the residue VAL14
of HBD2 for mobile disulphide SA (left) versus normal SA (right). The torsional region
sampled by the native NMR structures Is shown in red on both plots. The sampling
























































5.4. "In vivo" BH folding
Experimental and theoretical studies of proteins such as Bamase and Chymotrypsin inhibitor
2 (CI2) indicate that small molecule folding occurs via nucleated intermediates22'34"44 in a two
state3645 or three state process".
In this Section the possibility of nucleation events directing (correct) disulphide-bridge and
loop formation is investigated with a dynamic disulphide-bridge-BH algorithm. With this
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procedure an initial nucleating amino acid sequence is sequentially grown and successively
optimised with BH. It is hoped that preliminary folding events provide a molecular scaffold
for subsequent folding events in a manner that directs better loop formation. This strategy
therefore remains a possibility for both folding proteins, and also for generating families of
differently configured (and kinetically trapped) loop regions (the structures of which can
then be used by other algorithms).
5.4.1. Method
A schematic representation of the process is given in Figure 5.4.1.1. Bonds are formed and
broken with the standard procedure following every elongation phase. Geometric
optimization is carried out at each stage with GMIN 2.2.1 using 200-500 BH steps. Bonding
within this framework is achieved by altering the GMIN input file with an appropriate cshell
script (that invokes the same probabilistic bonding algorithm as with the MD case).
5.4.1. Results and discussion
Preliminary results with this method do not support the notion that productive nucleation is
possible from an N-terminal residue seed (Figure 5.4.2.1). Indeed, both HBD1 and HBD3
fail to exhibit correct torsional sampling for residues in key loop regions** (Figure 5.4.2.2).
However, despite this undesirable result, it remains a possibility that there could be
beneficial nucleation from different sequence seeds. For example, it is conceivable that
seeding an "/« vivo" simulation from a hydrophobic portion of the sequence could give rise
to a productive hydrophobic core, as observed in the two-state hydrophobic collapse model46"
4S). The GMIN parameter set may not be well optimized for this class of problem, and thus,
future work will also focus on developing more applicable parameter sets.
There are no results for HBD2 for the reason stated in chapter 4; namely that GMIN has some
trouble dealing with N-terminal proline torsional variations.
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Figure 5.4.1.1. Schematic representation of the "in vivo folding" code.
Initial nucleus
I
► Applv GMIN optimisation
4
Loop while i < n
i = i+\
No
Grow chain by single
amino acid
4
— Make a bond?
I Yes





A "seeding" approach may offer an additional means of generating geometrically favourable
starting configurations with correct (or partially correct) relative folds. This method is
attractive because simulation time is in the order of hours.
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Figure 5.4.2.1. A cartoon representation of HBD1 and HBD3 following the "in vivo" folding




Figure 5.4.2.2. Torsional dihedral angles for the residue LYS 31 (of HBD1) and GLY 31 (of
HBD3). The native NMR sampled regions are shown schematically in red and illustrate that
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5.5. Computational resource comparison of folding algorithms
Computational resource availability is frequently a limiting factor in solving any protein
folding problem. Indeed, were infinite computer power in existence, the field of protein
folding would not exist because the global minimum would be located by simple, exhaustive
sampling. A brief comparison of the resource consumption of each algorithm is here
presented so that the algorithm in question can be weighed alongside its computational
efficiency (Figure 5.5.1.1).
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Figure 5.5.1.1. A relative comparison of computational resource use for different folding
algorithms. Keywords: "BB" - Backbone, "eye" - cycles, "iter" - iterations, "MOB" - Mobile
disulphide bridge procedure. All non-RE resource use refers to total CPU time within a Dual
core, Xeon, 2.8GHZ, 1 MB RAM system. RE is conducted on IBM Bluegene and the time
quote in this instance refers to the total time taken for a 512 processor submission.
5.6. Conclusion
The in silico evidence suggests strongly that the failure of static-bond folding algorithms to
solve the defensin problem lies with their inability to rearrange incorrect disulphide cross-
linked loop-regions into native (or "more" native) loops and folds. The dynamic-bond
folding strategy, whilst being unable to locate the global structure, nevertheless alleviates the
problem of kinetic trapping ubiquitous to static-bond procedures. Indeed, the ability to
rearrange bonds dynamically will likely be an essential requirement of future cross-linked
protein folding strategies. The work presented here is a first attempt at modelling dynamic
bond formation and deals only with canonical pairings. Future work will centre on including
non-canonical connectivities into the repertoire of Hamiltonian states.
126
Chapter Five - Rational Structure Prediction: Probabilistic Disulphide Bridge Algorithms
5.6.1. Are cross-links a help or a hindrance?
It was originally hoped that the innate cross-linking within the (I-defensin family of proteins
would reduce the available conformational space, and hence make the folding problem easier
to conquer. The results presented here at first glance indicate the opposite; that a restricted
conformational space inhibits beneficial sampling. However, the true picture is likely more
complex than this. A well designed algorithm should be able to take advantage of both
restricted and unrestricted conformational space by selectively invoking dynamic and static
descriptions of the molecular system. In this way, dynamic bond descriptions would sample
globally by allowing different loop configurations to be explored, and static-bond
descriptions would sample locally within a given, beneficially restricted region. Cross-
linking, invoked at the right moment, would therefore likely provide a useful means of
selectively ignoring undesirable regions of potential energy space. The probabilistic SA
algorithm presented in this chapter provides the first combined dynamic-static approach to
tackling the problem and future work will focus on improving the basis for switching
between global and local sampling.
5.6.2. Future work
There may not be a single best strategy for folding defensins. Indeed, the answer may lie
with combining many strategies. For example, it may well be that backbone mapping
provides a good initial structure from which to begin, and that subsequent algorithms can
then solve this partially native structure. Future methodologies (as stated in Section 5.6.1)
will focus on combining aspects of both dynamic and static bond descriptions. For example,
one idea (in developmental progress) is to invoke a dynamic-static disulphide bridge
depiction of the molecular system within a RE framework. In this scheme every replica but
one is permitted to interchange between canonical and non-canonical connectivities using the
dynamic bond scheme. The remaining replica is then fixed with the correct, static, canonical
pairing. In this way, replicas at high temperatures (and with dynamic disulphide bridge
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arrangements) are permitted random walks to a low energy, canonically connected replica in
which restricted local sampling can occur. A modified RE procedure of this nature requires a
hybrid Hamiltonian description of the system in which exchange events are evaluated with a
single, wholly non-bonded system Hamiltonian, whilst production MD is generated with
Hamiltonians that corresponded to the respective canonical and non-canonical pairings*.
5.7. Standard simulation settings
All MD and minimizations are run (unless otherwise specified) with the settings in Table
5.7.2 and Table 5.7.3. Computer code for implementing PE sampling is written in cshell or
FORTRAN. The CD contains all the written code.
Table 5.7.1. Standard xleap commands. See Appendix for further xleap explanations.










bond seq. 13.SG seq.34.SG In this case the "SG" atom
of residue 13 and 34 are






molecule to be saved,
"seq.parm" refers to the
topology file (or
Hamiltonian) and "seq.crd"
refers to the coordinate file.
Load pdb file using
existing sequence with
name "seq".
seq = loadpdbusingseq seq.pdb
(NALA ARG ARG CLYS)
This command is often
useful when superimposing
a modified sequence onto a
pre-existing set of
coodinates.
Save pdb file to disk savepdb seq seq.pdb "seq.pdb" refers to the
name of the pdb file to be
saved.
AMBER 9 possesses a hybrid Hamiltonian facility that has historically been invoked to perform
replica exchange in an explicit solvent environment but with an implicit solvent exchange criterion49.
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Table 5.7.2 Standard MD settings
Parameter Setting Explanation
nstlim 1000 Number of femtoseconds for MD run
igb 0 or 2 Set the implicit solvent enviromnent (0 = gas-phase
simulation) 2 = standard Born solvent simulation.
dt 0.001 or 0.002 Time step for simulation in picoseconds.
nit 1 (3 when gb=2) ntt=l: Employ constant temperature using weak coupling
algorithm16.
ntt=3: Employ Langevin dynamics.
tempO Dynamic setting Specify the target temperature for an MD run. This value
is varied depending on the simulation. For SA this is
varied from 800K to OK. For standard dynamics this is
set to 300k.
ntf 2 Ignore contributions from Hydrogen when forming
interaction matrix.
ntc 2 Constrain bonds involving Hydrogen.
Table 5.7.3. Standard minimization settings
Parameter Setting Explanation
Maxcvcl 50 000 Maximum number of allowed minimization cycles.
Drms 0.005 The convergence criteria determined by the root mean
square force (kcal/mol)
Ntpr 1000 Sample energy information every 1000 steps.
Ntmin 1 Perform steepest descend minimization for n cycles and
then switch to conjugate gradient descent.
Ncvcl 100 Perform steepest descent minimization for 100 cycles.
Igb 0 or 1 Default minimization in gas-phase or Born solvent
environment.
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A key assumption of this work is that defensin antimicrobial activity depends on, and follows
preliminary binding to key components of the bacterial cell surface. Molecular models are
therefore required for both the defensin and the presumed binding partner (lipid A). The
AMBER1 residue library contains standard amino acids (for describing proteins) but no
appropriate organic molecules for modelling lipid A. This Chapter discusses how the required
non-standard residues are created and Chapter Seven discusses how these same residues interact
with defensins.
6.1.1. Developmental background and scope
A central challenge of molecular simulation is to simulate accurately the properties and
conformational behaviour of as wide a range of molecules as possible. Historically, force-field
software was developed and parameterised to deal with proteins and nucleic acids1'2, and as
such, the repertoire of organic molecules available within the standard force-field libraries is
comparatively limited. Increasingly, resources are being directed at developing a "generalised"
set of parameters that can be applied with reproducible results to a wide range of organic
molecules3"6. This research invokes the widely tested generalised AMBER forcefield1 (or "gaff7
as it is commonly referred to) for which abundant agreement has been observed with
experimentally derived geometries, hydrogen-bond energies, and relative conformational-
energies3. The gaff parameter set in conjunction with an appropriate charge derivation method
enjoys wide use in research fields that span everything from predicting melting and liquid
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properties of simple organic molecules7 to molecular docking studies8"10 to predicting dispersive
X-ray diffraction spectra".
6.2. Method
The energy of a molecular system can be approximated with a force-field equation that consists
of bonded and non-bonded interaction terms (Chapter Three). The challenge of developing a
non-standard residue therefore rests with calculating (or approximating) the following force-field
parameters:
1. Partial charges for each atom centre.
2. Force-constants that describe bond-angle bending and dihedral torsional variation.
3. Van der Waals radii.
All residue development is performed with the AMBER antechamber component (and its related
subprograms). All residue equilibration is performed in explicit SPC12 solvent using standard
MD settings (Section 6.5).
6.2.1 Obtaining the starting geometry and assigning global charge
The initial coordinate geometry of LPS is taken from the E. coli K-12 AW740 strain of bacteria
for which the crystal structure is solved in complex with the porin protein Fhua1314. Missing
hydrogen atoms are added to lipid A using the xleap facility ofAMBER.
Most literature published structures of lipid A assume that each phosphate group possesses a unit
negative charge15"20. This is a reasonable assumption because generic phosphate species with a -1
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charge state display a pKa of 6.7, whereas the neutral and -2 charge state exhibit pKa's of 2 and
12 respectively21. In reality, the assumption of a -1 charge state may be incorrect because the
local chemical environment (that is not a priori known) undoubtedly plays a role in determining
the local pH. However, despite this potential pitfall, and in the absence of the desired
experimental evidence for a definitive charge state, the global charge assignment in this work
follows the assumptions of previous work1 ~20.
6.2.2. Modelling strategy
The defensin-Lipid A problem is tackled in a "bottom-up" approach in which a simplistic model
is gradually refined towards a more complex one. In the first level of this model a major
simplifying assumption is that the phosphorylated glucosamine region of the molecule is
responsible for most of the vital docking interactions. This conjecture reflects the experimental
observation that cationic modifications to this moiety correlate with AMP resistance18'22"24 and
that rationally designed peptides based on properties common to many AMPs bind this same
region25. With this rationality in mind, and for purposes of computational tractability, the KDO
and lipid region of the molecule are cleaved from the central glucosamine core (Figures 6.2.2.1).
The charge and parameter fitting procedure, as well as the ab initio and MD geometry
optimisation are summarised in Figure 6.2.2.2.
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Figure 6.2.2.1. A schematic representation of Lipid A bound to KDO. The fatty acid chains and
KDO residues are cleaved at regions that intersect with the red box. Only the central tri-
phosphorylated sacharide region remains. "Floating" bonds generated by the cleaving process
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Figure 6.2.2.2. Flow diagram of residue development strategy showing both the software used
and the information flow.
















Combine with standard residues
and perform simulation.
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6.2.3. Optimisation
Hydrogen atoms are added to the crystal structure of the cleaved Lipid A using thcxleap module
of AMBER. The resulting structure is then optimised with Gaussian 0326 using the HF/6-31G*
level of theory, tight convergence, and the "iop(6/33=2) iop(6/42=6)" keyword for establishing
atomic centres.
6.2.4. Charge fitting
The standard AMBER resp21 procedure is used to fit partial charges to the quantum
mechanically optimised lipid A structure (in which the electrostatic potential has been calculated
at the HF/6-31G* level of theory). It is worth noting that more representative charges can be
obtained by performing a Boltzmann weighted average of an ensemble of different MD sampled
trajectories28. This approach, whilst offering increases in accuracy, is computationally extremely
expensive and not considered in this simplified model of initial interactions, though it is a
common practice for many residues that are rigorously developed28'29.
6.2.5. Parameter fitting and MD equilibration
Parameters are fitted with the AMBER generalised force field parameter set {gaff)3 using the
antechamber module of AMBER. The bond force constants fitted to the "p5-oh-ho" connectivity
are artificially strengthened by a factor of 10 in order to prevent dynamic instability that is
symptomatic ofAMBER force-field (over)simplifications*. The parameterised, charge fitted and
geometry optimised construct is then subjected to MD equilibration for 1 nanosecond with SPC
explicit solvation (The process ofMD equilibration is discussed in Section 6.5 of this Chapter).
*
According to Mike Crowley (a principle architect of AMBER) the van der Waals interaction term is not
computed for directly neighbouring atoms because the energy barrier to angle bending between such
neighbours is assumed to be high enough to prevent atomic overlap. However, this assumption does not
hold for the "p5-oh-ho" connectivity within the highly polar system investigated here. Hence, without
artificially strengthening the bond, extreme (and spurious) energies arise as a result of van der Waals
overlap.
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Finally, the resulting geometry is used to generate a standard AMBER residue (or "prep") file
using the standard antechamber procedure.
6.2.6. Mutations and variations
a) 4-deoxy-4-aminoarabinose (Ara4N)
Lipid A is the primary immunogenic stimulant within LPS and (unsurprisingly) a
number of cationic modifications to it are associated with resistance to AMP attack.
One notable mutation that is examined in this research is the addition of Ara4N to
the diglucosamine phosphate residues22'23. The Ara4N residue is accordingly created
de novo within xleap from a literature published connectivity22. The structure is
optimised with Gaussian and subsequently attached covalently (using xleap) to the
diglucosamine residue in place of the single phosphate group.
b) Bis-phosphorylated diglucosamine (BPDG)
There are many serum (and species) dependent lipid A variants. Some of these are
confined to the lipid region24'30'31 whilst others are confined to the glucosamine
core32. The bis-phosphorylated variant (Figure 6.2.6.1.) is common and (like the tri-
phosphorylated species) is investigated in Chapter Six. The necessary removal of a
phosphate group from the tri-phosphorylated species is performed using xleap and
the standard procedure followed for optimisation, charge derivation and parameter
fitting (Section 6.2.2 -5).
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Figure 6.2.6.1. BPDG does not possess the terminal phosphate group (marked in red).
6.3. Results and discussion
6.3.1. Equilibration and production MD
Stable MD trajectories are obtained for each of the model structures within explicit solvent**. An
example energy and temperature output for Ara4N (Figure 6.3.1.1 A and B) and the other
molecules follow similar behaviour (provided on CD). The standard equilibration and production
procedure and parameters are given in Section 6.5.
6.3.2. Charge fitting and geometry optimisation
a) Tri-phosphorylated-diglucosamine (TPDG)
The MD equilibrated and minimized structure is shown in Figure 6.3.2.1. The
regions of the molecule that would (ordinarily) attach to fatty acid chains are
organised in a single plane similar to that found in the crystal structure. Partial
charges for the atomic centres are shown in Table 6.3.2.2.
"
Stable trajectories are not obtained for gas-phase MD, even despite artificially strengthening the p5-oh-
bo bond. The reason for this is not clear though it is likely to result from the same AMBER
(over)simplification. Many residues with "normal" levels of charge polarisation give rise to predietably
stable dynamics.
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b) Bis-phosphorylated diglucosamine (BPDG)
The BPDG species adopts a very similar structure to the tri-phosphorylated variant
{Figure 6.3.2.3) and the partial charge assignments do not differ substantially for
atoms outside the immediate vicinity of the cleaved phosphate residue.
c) Aminoarabinose-modified BPDG (Ara4N)
Ara4N, following MD equilibration and minimization gives rise to a geometry in
which the aminoarabinose moiety sits parallel to the plane of (what would otherwise
be) the extending fatty acid chains {Figure 6.3.2.5.). The partial charges for each of
the atomic centres are shown in Table 6.3.2.6.
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Figure 6.3.1.1. 1 nanosecond of production MD Ara4N. Production runs for other constructs
follow a similar pattern and are not shown. A. Energy vs MD time and B. Temperature vs MD
time.
A
0 200 400 600 800 1000
MD time/ps
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Figure 6.3.2.1. The optimised, parameterised and charge fitted structure of TPDG.
Carbon atoms are shown in turquoise, hydrogen in white, oxygen in red, phosphate in
brown and nitrogen in navy blue.
Table 6.3.2.2. Partial charges for each of the atomic centres of TPDG. The library files for this










C13 -0.076760 C20 0.940720 C5 0.353330 H26 0.1 18830
H18 0.064640 C21 -0.487850 03 -0.567540 H27 0.1 18830
H19 0.064640 H31 0.128210 H5 0.025520 012 -0.689500
H20 0.064640 H32 0.128210 C4 -0.018210 H2 0.157370
07 -0.318570 H33 0.128210 02 -0.710260 CI 0.580280
C12 -0.013590 015 -0.657360 H9 0.442330 HI 0.088280
H15 0.123450 C8 0.044970 H4 0.198970 Ol -0.537400
H17 0.123450 N2 -0.798980 C3 0.384320 P2 1.320280
Cll 0.108890 H16 0.386560 H3 0.120440 017 -0.825980
06 -0.348900 C14 0.913680 014 -0.539110 018 -0.825980
H14 0.072470 C15 -0.503390 C18 1.017340 019 -0.605700
CIO -0.116300 H21 0.125320 C19 -0.434040 P3 1.403300
05 -0.433270 H22 0.125320 H28 0.107910 021 -0.787990
PI 1.305310 H23 0.125320 H29 0.107910 H34 0.456390
09 -0.782600 08 -0.668890 H30 0.107910 022 -0.839710
H24 0.438610 Hll 0.174200 013 -0.728490 020 -0.839710
010 -0.811080 C7 0.214790 C2 -0.434970 H25 0.118830
Oil -0.811080 H10 0.120680 N1 -0.423110 H7 0.044610
H13 0.143630 04 -0.347260 H8 0.314200 016 0.109170
C9 0.277120 C6 0.055190 C16 0.812960
H12 0.096380 H6 0.044610 C17 -0.461670
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Figure 6.3.2.3. A liquorice depiction of BPDG. Carbon atoms are shown in turqoiuse, hydrogen
in white, oxygen in red, phosphate in brown and nitrogen in navy blue.
Table 6.3.2.4. Partial charges for each of the atomic centre of BPDG. The library files for this










CIO -0.368800 08 -0.670000 010 -0.311740 C19 0.784920
H14 0.093160 C4 -0.028620 C12 -0.073220 C20 -0.417070
H15 0.093160 03 -0.558910 H19 0.093090 H29 0.115180
H16 0.093160 PI 1.330950 H20 0.093090 H30 0.115180
C9 0.780680 04 -0.712390 C13 0.446240 H31 0.115180
09 -0.627280 H7 0.413440 H21 -0.004230 015 -0.667970
N1 -0.602200 05 -0.825440 C14 0.057350 H32 0.173500
H13 0.356340 06 -0.825440 012 -0.711070 CIS 0.429560
C8 -0.191120 H8 0.171650 H22 0.442770 H24 0.070980
H17 0.197310 C3 0.167090 H23 0.075940 013 -0.584420
C5 0.283310 C2 0.019890 Oil -0.595660 C16 0.948340
H9 0.083870 Ol -0.425810 C21 0.598610 014 -0.663110
07 -0.446080 CI 0.036890 H33 0.082930 C17 -0.407220
C6 -0.446080 HI 0.050060 016 -0.532290 H25 0.109170
C7 -0.537960 H2 0.050060 P2 1.279830 H26 0.109170
H10 0.143240 H3 0.050060 017 -0.702220 H27 0.109170
Hll 0.143240 H4 0.115100 H34 0.411820 02 -0.428720
H12 0.143240 H5 0.115100 018 -0.795460 H18 0.029310
H6 0.115100 02 -0.428720 Cll 0.399920 H28 0.297850
019 -0.795460 C18 -0.389660 N2 -0.454160
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Figure 6.3.2.5. The optimised, parameterised and charge fitted structure of Ara4N. Carbon
atoms are shown in turquoise, hydrogen in white, oxygen in red, phosphate in brown and
nitrogen in navy blue.
Table 6.3.2.6. Partial charges for each of the atomic centre of Aminoarbinose modified BPDG.










CI -0.48918 05 -0.66466 C13 0.19084 H30 0.1291
HI 0.11905 H10 0.39925 H21 0.05255 H31 0.1291
H2 0.11905 06 -0.84578 015 -0.36864 014 -0.7211
H3 0.11905 07 -0.84578 C14 0.17044 H32 0.12726
C2 0.85589 HI 1 0.11525 Oil -0.64743 C21 0.3291
Ol -0.67302 C8 0.02489 H22 0.39139 H33 0.0963
N1 -0.67360 C9 0.16742 H23 0.17408 016 -0.38521
H4 0.35327 08 -0.41867 C15 0.08649 P2 1.09674
C3 0.0251 CIO 0.02777 H24 0.08703 017 -0.77418
H5 0.18241 H12 0.05225 012 -0.5008 018 -0.77418
C4 0.07618 H13 0.05225 C16 0.93417 019 -0.36496
H6 0.11916 H14 0.05225 C17 -0.57756 C22 0.34138
02 -0.40563 H15 0.06832 H25 0.1594 H34 0.1545
C5 0.92903 H16 0.06832 H26 0.1594 020 -0.46606
C6 -0.54324 H17 0.09303 H27 0.1594 C23 -0.04247
H7 0.1582 09 -0.40918 013 -0.64669 H35 0.13982
H8 0.1582 Cll 0.35267 C18 0.00186 H36 0.13982
H9 0.1582 H18 0.07025 N2 -0.628 C24 0.34557
03 -0.6618 010 -0.4144 H28 0.41807 021 -0.61472
C7 0.17285 C12 0.00308 C19 0.84412 H37 0.44816
04 -0.56621 H19 0.08412 C20 -0.44087 N3 -0.64352
PI 1.31513 H20 0.08412 H29 0.1291 H38 0.41971
H39 0.41971 H40 0.41971 C25 0.25481 022 -0.719670
H41 0.49001 H42 0.09725 C26 -0.078920
H44 0.48300 023 -0.70440 H43 0.115110
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6.4. Conclusion
The non-standard residues discussed in this Chapter represent a first attempt at modelling the
underlying interactions of the defensin-lipid A problem. Three potential shortcomings of these
(substantial) simplifications are:
1. Atomic charges in reality vary in response to changes in geometry. There is no
attempt with this model to get a more representative charge via a Boltzmann
weighted average of charge states obtained from many geometries.
2. The (cleaved) lipid portion and core region might, in reality, affect the structure and
charge properties of the glucosamine region.
3. Defensins in reality may interact with other components of lipid A, and not merely
the presumed region. (There is some evidence that modifications to the lipid A fatty
acid region also direct defensin resistance33).
Chapter Seven explores the binding between TPDG, BPDG, Ara4N and defensins HBD1-3. An
in-depth discussion is provided in this Chapter of the benefits and drawbacks of a simplified
lipid A representation. Conclusions are also drawn about the nature and mode (if any) of
binding.
6.5. Standard Settings
Equilibration in this Chapter refers to four separate equilibration steps within an explicit SPC
solvent milieu (.Figure 6.5.1). The corresponding parameter settings are also provided (Table
6.5.2). The four step equilibration process allows atomic overlap to be relieved (between solvent
and solute), and stable values to be obtained for density, volume and temperature prior to
production MD.
144
Chapter Six - Residue Development
Figure 6.5.1. A schematic representation of MP equilibration and production.
Stepl: Minimize solvent, keep solute fixed
I
Step2: Perform solvent and solute minimization
I
Step 3: MD density equilibration of solvent
I
Step 4: MD equilibration of solvent and solute
I
Step 5: Production MD
Table 6.5.2. Parameters for steps 1-4 (figure 6.5.1.) using SPC explicit solvent.
Parameter Value Comment
Step 1 solvent minimization.
ncyc 500 Number of steepest descent iterations.
maxcvc 1000 Maximum number of permitted iterations.
drms 0.005 Root mean square force threshold for stopping minimization.
ntb 1 Maintain periodic boundary conditions.
ntr 1 Apply harmonic restraint to solvent.
cut 12 Non-bonded cut-off.
Step 2 Solvent + solute minimization.
ncyc 1000
maxcyc 10000





Step 3 Density equilibration of water.
cut 12
ntr 1 Restrain solute.
ntc 2 Ignore contributions from Hydrogen.
ntf 2 Constrain bonds involving Hydrogen.
tempi 0 Initial MD temperature /K.
tempO 300 Final temperature /K.
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nit 3 Turn on Langevin dynamics.
gamma In 1 Collision frequency for Langevin equation.
nstlim 10
000
Number ofMD steps to perform.
dt 0.02 Use a 2 femtosecond time-step.





Number ofMD steps to perform.
dt 0.02 Use a 2 femtosecond time-step.
cut 12
ntr 1 Restrain solute.
ntc 2 Ignore contributions from Hydrogen.
ntf 2 Constrain bonds involving Hydrogen.
tempi 0 Initial MD temperature /K.
tempO 300 Final temperature /K.
ntb 1 Use periodic boundary conditions.
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This Chapter investigates the interaction of the sacharide-based residues (discussed in Chapter
Six) with HBD1-3. As stated in Chapter Two, mutant isolates of bacteria that possess cationic
modifications to their Lipid A components are resistant to dcfensin attack1"6. This Chapter
investigates the premise that /Tdefensins target the sacharide component of lipid A during the
first (presumed) step of antimicrobial attack.
7.1.1. Previous simulation work with antimicrobial peptides
Frecer et. al1 provide the only notable simulation of antimicrobial peptides interacting with
surface markers of bacterial membranes. In their work in 2004 they attempt (with some success)
a rational design of a novel antimicrobial agent in which key properties of common AMPs
(magainins, ccprocins defensins and others)7 are mimicked. In this approach a flexible, induced-
fit docking procedure is used to generate 100 bound configurations with lipid A, the resulting
structures of which are ranked on the basis of their relative interaction energies. Interestingly, the
best ranked structures are found to attach to the sacharidc region of the molecule7. Experimental
synthesis of these compounds reveals a killing propensity for E.coli, Klebsiella pneumoniae, and
P. aeruginosa that exceeds conventional antibiotics. For example, the minimum inhibitory
concentration of tetracycline for these strains is in the region of 3pg/ml8, compared to that of the
most potent rational product, which possesses an MIC of 10ng/ml7. These tentative findings
suggest a key role for lipid A in the antimicrobial mechanism of a variety of AMPs.
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Unfortunately, a conspicuous absence of native NMR and crystallographic data for most cell
surface markers has resulted in rather few AMP-receptor simulations. Consequently, the vast
majority of membrane-AMP simulations are directed at elucidating the mechanism of bilayer
permeation. An excellent example of this work is detailed by Berneche el al, who, in 1998
produced an all-atom model of melittin insertion into the lipid bilayer9. In this simulation
melittin was found to partially permeate the bilayer and weaken the integrity of the membrane
enough to allow a water channel to form. Similar work by Khandelia et al. in 2005 involved an
SDS micelle binding with the antimicrobial peptide ovispirin1011. Essex at al. investigate
permeation of the bilayers by a number of small, organic molecules12, as well as the dynamic
behaviour of solutes within the bilayer itself11.
7.1.2. The docking problem
The problem of ligand docking is two-fold; that of sampling the ligand-receptor potential energy
space, and that of ranking the resulting complexes. There are an enormous (and growing) range
of algorithms for tackling this problem14"16, the choice of which depends on the nature of the
investigation: Is the location of the active site known? Is the identity of the ligand known? How
many ligand variations require screening? What are the available computational resources? In
the case of the disaccharidc-lipid A docking problem neither the binding site, nor the initial
conformation (before binding), nor the final conformation (after binding) are known. The
sampling technique for this problem thus employs a flexible, MD approach that bares some
resemblance to the one implemented by Frecer et al.1 and indeed, a variety of other small-
molecule MD-docking studies17"10. Non-MD strategies often make use ofMonte Carlo or genetic
algorithm-generated structural perturbations (Software packages such as AutoDock often employ
a combination of both "random move" and MD strategies21"23).
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A full description of all the available docking methods is beyond the scope of this introduction
and the interested reader is invited to consult the excellent reviews by Essex14 and Halperin'y
7.2. Method
The docking procedure makes use of a flexible MD-based method in conjunction with a relative-
free-energy scoring procedure. Absolute binding free energies are computed only for the 3 best
ranked structures of each of HBD1-3. These best ranked structures are then subjected to Ara4N
and BPDG mutations (Chapter Six) with a view to elucidating some - or in a perfect world, all -
of the binding complexities.
7.2.1. Docking strategy
Preliminary binding configurations are generated by manually placing the lipid A moiety in
various (rationally intuitive) regions of the molecular surface of the peptide using VMD24.
Explicit solvation of each of these docked structures with the SPC23 water model is then
followed by several MD simulated annealing runs (see Section 7.5 for parameter settings).
Finally, each of these annealed structures is exposed to explicitly solvated molecular dynamics
for 2 ns (Table 7.2.1.1, Figure 7.2.1.2 and Table 7.2.1.3). The total number of docks for a given
peptide and binding partner is thus given by NDocks x NSA , where NDoclcs refers to the number of
initial, VMD generated docks, and where NSA refers to the number of simulated annealing
cycles.
150
ter Seven - Molecular Docking
Table 7.2.1.1. Docking and MD procedure.
Procedure Software/process Comment
Initial structures Generated using VMD Manual docking proved to be most
reliable form of generating initial
structures.
Simulated annealing Sander and cshell code The annealing protocol employs
stochastic temperature and time
control for better sampling.
Final equilibriation Sander and cshell code Allow further relaxation and
substrate surface movement.
Free energy scoring AMBER MM-PBSA protocol Free energy calculations permit
effective comparison of binding,
more so than a simple "binding
energy" paradigm.
Table 7.2.1.3. Periodic boundary-simulation set-up. The manually docked complex is solvated
within xleap and neutralized with counter ions.
HBD1 HBD2 HB3
Periodic box dimensions/A x: 52.981 x: 46.645 x: 65.419
y: 49.027 y: 52.874 y: 62.245
z: 48.270 z: 50.124 z: 42.040
Representative water particles2 2740 2761 3905
Number of CI" counter ions 1 4 8
7.2.2. Testing for dissociation
Defensin-substratc dissociation is tested for by tracking the Euclidean distance between atoms
that are buried within each of the molecular interiors of the defensin and substrate respectively.
A 30 Angstrom threshold is used to distinguish between bound and unbound states.
2 The number of water particles varies for each different orientation of ligand and defensin. The value
shown is representative in general magnitude only.
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Figure 7.2.1.2. Schematic representation of clocking procedure.


















Extended dynamics: discard dissociated docks
I
Calculate binding tree energy
Most stable docked structures
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7.2.3. Scoring
Structures that remain bound following the first nanosecond of extended dynamics are scored on
the basis of a relative MM-PBSA26"29 free-energy comparison (Chapter Three). With this
method the free energy is expressed as a sum of individual contributions30"32:
G = Emi +GP+ Gnp - TSsolute (1)
Where EMM refers to the molecular mechanical energy, GP refers to the polar free energy, GNP to
the non-polar free energy, T to the temperature of the simulation, and S to the solute entropy.
It is common practice to apply the method to a variety of trajectory snapshots so that a
conformationally averaged free-energy value is obtained"10"42. In this study the first stage of free
energy scoring (for the purpose of reducing computational time) makes use of a single
minimized structure. Interestingly, Kuhn et al. detail instances in which such single, minimized
complexes give rise to comparatively more accurate free-energy values43. The final absolute free
energies of the best ranked structures are therefore computed using both strategies for
comparison sake.
The AMBER implementation ofMM-PBSA used in this research estimates polar solvation free-
energies with the PBSA procedure26, non-polar contributions with the Molsurf4 program and
desolvation free energies with the GB component of sander45'41. The external salt concentration
used for the Poisson-Boltzmann solver is set to a physiologically credible 0.15 M48. For each
docked complex 50 trajectories are examined, each set of which is extracted from the final 500ps
of MD. Details of the parameters used are given in Table 6.2.3.
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The entropic penalty of binding is presumed to be very similar for any identical collection of
docked complexes and, as such, entropic factors are ignored in the scoring model.
7.2.4. Absolute binding free-energies
In order to establish a binding hierarchy between [3-defensins HBD1,2 and 3, it is necessary to
consider entropic factors. Accordingly, absolute binding-free energies are computed by
correcting the relative binding energy (discussed in section 7.2.3.) with the entropic penalty
associated with docking41. Thus,
Binding = relative ~ TASsolute (2)
Where AGBindjng refers to the free energy of binding within a solvent environment, AGrelalive
refers to the relative free energy change upon binding (as set out in equation J), T to temperature
and ASsolute to the entropy change upon solute binding.
Entropic contributions are estimated with a normal mode analysis using the nmoc/e module of
AMBER as detailed in other work30"32'40.
7.2.5. Variations to lipid A
Chapter Six discusses two mutant lipid A variants. The first, 4-deoxy-4-L-arabinose (Ara4N), is
associated with increased resistance to AMP attack6'49. The second, a bis-phosphorylatcd species
(.BPDG), is predominant within Escherichia coli K-12. This variant, with one less phosphate than
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the tri-phosphorylated variant (which is considered in the docking procedure), possesses both a
lower net charge (-2 instead of -3) and a lower level of internal polarization. The effect of both
these variants (Ara4N and BPDG) is investigated here by mutating, in situ, the best 3 ranked
TPDG-defensin complexes. (The mutations are generated with the aid of a cshell script that
superimposes the coordinates of the mutant onto the wild-type structure and redefines the
AMBER atom names appropriately - see CD for code). Following the mutations, further MD
equilibration is performed (with standard settings - Section 7.5) and a relative and absolute
binding energy comparison made (as outlined in Sections 7.2.3 and 7.2.4).
7.3. Results and discussion
A number of assumptions are made in this docking study. These are:
1. That the lipid A region forms the first, vital docking interactions with the approaching
defensin (Chapter Two).
2. That the charge distribution of a single, minimized lipid A molecule sufficiently
captures the average charge distribution for many conformational trajectories (Chapter
Six).
3. That the local chemical environment favours the existence of anionic phosphate moieties
(Chapter Six).
4. That the most important docking interactions can be modelled with a forcefield
approximation in an explicit water environment (Chapter Two and Chapter Three).
5. That the docking procedure (in conjunction with the scoring algorithm) locates a global
defensin-substrate binding-minimum (this Chapter).
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Where necessary these assumptions and their possible (or inherent) shortcomings are given their
full consideration in the proceeding sections.
7.3.1. SA and extended MD: Is a free-energy docking minimum located?
The docking problem possesses many more degrees of freedom than a single molecule protein
folding problem of equivalent size14, and thus, the predicted receptor-ligand geometry for many
classes of problem is often highly speculative. Indeed, whether or not a "true" free energy
docking minimum is located for this docking problem with an SA/MD approach cannot (at this
stage) be determined. Intennolecular receptor-ligand distance snapshots for each individual
complex do, however, suggest effective global and local sampling (example MD equilibration
and production statistics are provided in Figure 7.3.1.2 and backbone RMSD values for each
complex are given in Figure 7.3.1.1). It is assumed hereon that SA-sampling in conjunction with
extended MD locates a good (or global) minimum for this class of problem.
Figure 7.3.1.1. RMSD plots for initial SA docking. Large jumps in RMSD reflect manually
orientated docking positions, whilst small changes reflect the existence of local, SA-generated
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Figure 7.3.1.1 (continued). RMSD plots for initial SA docking. Large jumps in RMSD reflect
manually orientated docking positions, whilst small changes reflect the existence of local, SA-
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The extended MD runs provide, in addition to beneficial local sampling, a first level of binding
discrimination. Indeed, only four HBD1 and HBD2 complexes survive the initial Ins extended
MD phase (results not shown); a result in some contrast to that of the inherently more cationic
HBD3, for which there are twenty five stable complexes over the same time frame. A
comparison of charge versus binding accordingly suggests (at first glance) a large electrostatic
component to the observed binding stability. However, as will be shown in due course, hydrogen
bonding also plays a crucial role.
Figure 7.3.1.2. Example production statistics for a selected HBD2 run. Following initial
equilibration stable production statistics are generated for: A: energy, B: temperature, C:
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Figure 7.3.f.2.(continued) Example production statistics for a selected HBD2 run. Following
initial equilibration stable production statistics are generated for: A: energy, B: temperature, C:
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Figure 7.3.1.2.(continued) Example production statistics for a selected HBD2 run. Following
initial equilibration stable production statistics are generated for: A: energy, B: temperature, C:
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7.3.2. MM-MPSA scoring
Structures that survive the first nanosecond ofMD are subjected to an MM-PBSA free-energy
scoring comparison. For HBD1 and HBD2 the relative free energy of binding is insubstantial,
ranging from approximately +4 to -14 kcal/mol (Figure 7.3.2.1). This is in some contrast to the
many HBD3 complexes that possess a relative free energy of binding in excess of -50 kcal/mol
(.Figure 7.3.2.1). The best three ranked structures for each of HBD1-3 are provided in Figures
7.3.2.2 - 4 respectively.
The MM-PBSA method is approximate and suffers from two shortcomings:
1. The polar component of the free-energy term is determined with an implicit solvent
approximation; does this capture adequately the inhomogeneous and complex
electrostatic interactions that govern the docking landscape?
2. The non-polar free energy contribution makes use of an empirically derived solvent
exposed surface area parameter that is determined by averaging the non-polar properties
of many organic compounds'^0"1; does this averaging reflect the true hydrogen bonding
contribution for this docking problem?
The latter concern is given credence by the fact that implicitly solvated, docked complexes of
HBD1-3 are found to be stable during MD runs at 300K , 400K and 500K3. In each case, the
number of stable complexes in existence after 2 ns of production MD greatly exceeds that of the
explicitly solvated case. HBD1 and HBD2, for example, give rise to at least 12 stable
3
Many of these initial results were regrettably deleted in order to accommodate the large explicitly
solvated molecular data sets. Frustratingly, it was only following the explicit solvent study that the extent
of the inaccuracy of the implicit solvent model was realized, and henceforth, the (possible) importance of
hydrogen-bonding in the docking process.
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complexes, whilst the explicit solvent case gives rise to just 4. This finding suggests strongly
that the implicit solvent model inadequately captures the solvent milieu, and hence, that binding
comparisons based on it may be inaccurate. Future work will undoubtedly require an explicit
solvent free-energy binding comparison, perhaps incorporating a thermodynamic integration
approach32'52.
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Figure 7.3.2.2. The 3 best free-energy-ranked structures for each of HBD1. The structures are
ranked A-C in order of free-energy stabilization. The defensin in each case is depicted in a red
cartoon format, whilst the lipid A fragment is shown in liquorices in which phosphates appear
brown, oxygen red, nitrogen blue, and carbon, turquoise.
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Figure 7.3.2.3. The 3 best free-energy-ranked structures for each of HBD2. The structures are
ranked A-C in order of free-energy stabilization. The defensin in each case is depicted in a red
cartoon format, whilst the lipid A fragment is shown in liquorices in which phosphates appear
brown, oxygen red, nitrogen blue and carbon, turquoise.
A V
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Figure 7.3.2.4. The 3 best free-energy-ranked structures for each of HBD3. The structures are
ranked A-C in order of decreasing free-energy. The defensin in each case is depicted in a red
cartoon format, whilst the lipid A fragment is shown in liquorices format; phosphates are brown,
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7.3.3. Further MD of best ranked structures
Both HBD1 and HBD2 complexes dissociate within 300-400 ps and only HBD3 complexes
survive a further 2ns of production MD (results not shown). It is here on assumed that only
HBD3 is capable of eliciting stable binding, and as such, only HBD3 is further considered (in
section 7.3.4) for mutational analysis.
The best ranked HBD3 complexes bind TPDG in a pocket that lies partway between the N-
terminal region and the leading edge of the first (3-sheet. This finding is consistent with the Mass
spectrometric evidence of N-terminal DEFB14 defensin fragments" binding to heparin sulphate
(a similar double ring to TPDG with an identical -3 charge state). This is a tentative finding,
which, despite being a gas-phase study, supports the current in silico supposition that the N-
terminal region is crucial in forming initial docking interactions.
7.3.4. Binding insights from residue mutations: Is hydrogen bonding important?
The best three ranked HBD3-7PDG complexes (Section 7.3.3) are mutated in situ to incorporate
BPDG and Ara4N respectively. Extended MD (of 2 ns in duration) for each of these mutants
gives rise to dissociation in all but one instance (Figure 7.3.4.1). This finding contradicts (in
part) the prevailing belief that binding results from a "predominantly" electrostatic mechanism.
Indeed, whilst charge is almost certainly a factor in the observed binding efficiency of HBD3
compared to HBD1 and HBD2, it cannot be the sole factor in determining binding because, in
the context of a simple charge model, changing TPDG to Ara4N should correlate with a decrease
in binding stability; this is not observed - and neither, for that matter, is the expected variation
on mutating TPDG to the less anionic BPDG. These findings imply that a complex interplay of
electrostatic and hydrogen bonding interactions determine the binding mode, and not merely a
**
DIP stands for "defensin inspired peptide".s
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"simple" electrostatic mechanism, as has been postulated previously5307. Indeed, a hydrogen
bonding analysis of the MD trajectory for the system of TPDG-HBD3 reveals that interactions
with solvent outweigh (in terms of time occupancy) those with substrate (.Figure 7.3.4.3 and
Table 7.3.4.4). These findings, in addition to supporting a more complex view of (3-defensin-
substrate interactions, by extension challenge the assumption that resistance ofAra4Nmutants to
cationic antimicrobial peptides arises by virtue of a straightforward electrostatic mechanism in
which like-like charge repulsion thwarts initial binding events.
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Figure 7.3.4.1. A graph of extended MD versus intermolecular distance for HBD3 bound to each
of Ara4N and BPDG. Coordinate snapshots are sampled out of the trajectories in 5ps intervals.
Blue, red and black lines indicate the free-energy ranking of the structures from which MD is
seeded: blue, best ranked and black, worst ranked. Only one structure within Ara4N survives



















































Figure 7.3.4.2. MM-PBSA free-energy comparison of BPDG, TPDG and Ara4N. The trajectory
snapshot method is used as detailed in section 7.2.3 and 7.2.4. The free-energy values do not


















Figure 7.3.4.3. A graph showing relative hydrogen bonding occupancy for the best ranked
TPDG-HBD3 structure over a time frame of 800 ps. The red line shows hydrogen bonds formed
with solvent and the black line shows hydrogen bonds formed with HBD3. The numbers label
each interacting (or potentially interacting) atom. A relative occupancy of 0 indicates that no
hydrogen bonding is detected for the labelled atom. The graph illustrates that hydrogen bonding
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Table 7.3.4.4. Table showing the AMBER residues and corresponding atom names involved in
PDG-HBD3 hydrogen bonding. Red numbers (starting from the N-terminus) refer to HBD3 amino
acid residues whilst black ones refer to TPDG residues. Numbers within the index field map to
the atom references in Figure 7.3.4.3
Index Donor (atom Name) Acceptor (Atom Name) Bond Length
8 02 18 H:N 2.6875
12 015 34 HG:OG 2.875
1 45 OXT H24:09 2.859
6 26 0 H8:N1 2.897
2 24 0 H34 :021 2.924
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7.4. Conclusion
The ability of this model to elucidate the defensin structure-activity relationship depends on how
representative the inherent model assumptions and simplifications are of the biological reality.
As is discussed in section 7.1 the model system of lipid A deliberately excludes many
carbohydrate rings and fatty acid chains; are these components really just bulky spectators to the
docking process? (Resistance in some bacterial isolates correlates with variations to the fatty-
acid region of lipid A, and not to the GAG region49). Furthermore, are the partial atomic charges
representative? Are the protonation state assignments accurate for the local chemical milieu?
This model is a first, bottom-up attempt at capturing the underlying interactions that govern the
structure-activity relationship and caution must be observed when interpreting such a highly
simplified model. Indeed, until there is better experimental evidence and a more complete
understanding of the role (if any) of the other lipid A components, definitive conclusions
concerning the mode of action of this class of protein will be difficult to make. For the moment
is safe to say only that:
1. More atoms need to be included in the lipid A model (Do these, in reality, shield the
defensin-substrate interface from solvent interference?)
2. A more extensive sampling algorithm should be used and validated (where possible)
with experiment.
3. That the MM-PBSA scoring algorithm (due to its inability to capture the hydrogen
bonding contribution to binding) be improved (or exchanged for a better scoring
measure).
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However, assuming that the docking procedure locates a global minimum within a model
framework that captures vital docking interactions then two principle conclusions (discussed
below) can be drawn.
7.4.1. Failure of defensin to bind substrate is not a chance event
Most biological receptors are found to possess off rates in the region of 10"4 to 10"2 seconds"'"',8~61,
an observation in some contrast to that of the nanosecond timescale of defensin-substrate
dissociation observed in this study. Thus, assuming that the docking procedure locates a true
global binding minimum, it is likely that the failure ofHBD1 and HBD2 to remain bound during
the simulation time scale reflects a fundamental inability of the molecules to interact, and not
merely a chance offevent.
The same rationality implies that no firm conclusions can be drawn about the ability ofHBD3 to
bind TPDG, BPDG and Ara4N. hideed, it is conceivable that a longer simulation period in the
case of Ara4N and TPDG would result in dissociation. Whilst this remains a possibility, some
comfort can be drawn from the fact that the free energy of binding for TPDG exceeds that of
other known receptor-ligand interactions. For example, HBD3-7PDG possesses a calculated
absolute binding energy of -40 kcal/mol, which is in excess of the -13.2 kcal/mol calculated for
the reverse transcription inhibitor, TIBO31.
7.4.2. This study does not support the current resistance hypothesis
HBD3 is shown to bind to both BPDG and Ara4N with comparable binding free energies and
HBD1 and HBD2 are not shown to bind BPDG, TPDG or Ara4N at all. These observations do
not support the hypothesis that bacterial resistance to antimicrobial attack arises via disrupted
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lipid A-defensin binding events. However, as previously discussed, this research has not
examined the possibility that some (or all) defensins operate in a concerted manner. Indeed, it
may well be that effective binding is observed only in dimeric or trimeric forms of HBD1 and
HBD2. This remains a future investigative research area.
7.4.3. Binding is not a "simple" electrostatic process
The fact that HBD3 binds lipid A components strongly, but that HBD1 and HBD2 bind them
weakly (or not at all) illustrates a strong electrostatic component to docking. However, the large
observed disparity in the relative MD stability of explicitly and implicitly solvated receptor-
ligand complexes, along with the hydrogen bonding occupancies, show that hydrogen bonding is
also a significant factor. This inference is further supported by the observation that binding free
energy differences between Ara4N, BPDG and TPDG do not strictly obey an electrostatic
pattern (which would likely be the case if hydrogen bonding was indeed insignificant).
7.5. Standard settings
Unless otherwise stated, the parameters in Table 7.5.1 are used for free energy calculations.
Equilibration and production MD parameters used in this Chapter are identical to those
discussed in Chapter Six. SA parameters are provided in Table 7.5.2.
Table 7.5.1. MM-PBSA settings for determining relative free-energies of binding for defensin-
sacharide complexes.
Paramater description Value Comment
PROC 2 method of solving the Poisson Boltzmann (PB) equation.
This option refers to the PBSA method26.
REFE 0 Detemiines reference state for PB calculation.
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INDI 1.0 Dielectric constant for the solute.
EXDI 80.0 Dielectric constant for the external solvent.
SCALE 0.5 Lattice spacing in Angstroms for the number of grids. This
spacing has been shown to give stable and converged
values41'62.
LINIT 1000 Number of interactions with linear PB equation.
PRBRAD 1.4
ISTRNG 0.0 Ionic strength of the PB solvent.
RADIOPT 0 Set up radii from the prmtop file.
NPOPT 1 Use solvent accessible surface area to correlate total
nonpolar solvation free energy.
CAVITY SURFTEN 0.04352 Values used to compute the non-polar solvation free
energy. Other values used by Kuhn and Kollman vary, as
does that of Yan et. al Surften = 0.00542 kcal, b =
0.9236'62.
CAVITYOFFSET -1.008
SURFTEN 0.0072 Values used to compute the non-polar contribution to
desolvation.SURFOFF 0.00
DIELC 1.0 Dielectric constant for electrostatic interactions.
IGB 2 Onufriev's implementation of the Born solvent model47'63.
GBSA 1 Use LCPO method for surface area30
SALTCON 0.15 Concentration (in Mols) of counterions in solution. 0.1 -
1M used by Kolllman28. Physiological concentration is
often taken to be 0.15 M48.
EXTDIEL 80.0 Dielectric constant for the GB solvent.
INTDIEL 1.0 Dielectric constant for the GB solute.
SURFTEN 0.0072 Values used to compute the non-polar contribution of to
desolvation for GB model.SURFOFF 0.92
PROBE 0.0 Radius of the probe sphere used to calculate Surface Area.





520 MD at temperatures higher than this
can cause solute to denature.
cooling step/K Chosen stochastically.
Upper limit = 50, lower limit =10.
heating time/ps Chosen stochastically.
Upper limit = 50, lower limit = 14.
Varying heating times produce better
sampling than static ones.
cooling time /ps Chosen stochastically.
Upper limit = 30, lower limit = 10.
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The ultimate goal of this research is to elucidate the mechanism of defensin antimicrobial
activity so that new, effective and safe antibiotics can be developed to meet the growing
challenge of antibiotic resistance. A secondary aim is to develop a robust, in silico methodology
for predicting the native structure of p-defensins.
When considering an in silico approach to a biological problem it is important to realise the full
complexity of the reality that is being modelled. The prevailing evidence indicates that
biological systems balance on a thennodynamic and kinetic knife-edge. Mice, for example, are
known to become ill and die if they habitually ingest water with a deuterium content in excess of
50%'. The root of this toxicity lies in subtle changes in the quantum properties of hydrogen
bonding that presumably disrupt one or more vital biochemical reactions1. Experiments of this
ilk hint that there can be limitations to force-field approximations within a biological framework.
Indeed, force-field approximations, by their very nature, fail to capture the true characteristics of
the potential energy surface. Attempting to locate a global minimum on a potential energy
surface that does not correspond to the native structure remains a significant problem for all
force-field methods.
8.2. Rational Structure prediction
There are currently no correct, published rationally predicted native structures of any disulfide
cross-linked systems. The in silico work presented here suggests that this is (in part) because the
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singlc-Hamiltonian representations that current forcefield-based folding strategies invoke are
highly susceptible to local trapping on the potential energy landscape. The dynamic-bond
folding algorithm presented here (as part of a sampling algorithm) alleviates this trapping
problem and (in some cases) gives rise to comparatively better native secondary structures.
Failure to locate the native geometry might be because:
1. Too much time is spent sampling extended geometries in which no cross-linking is
defined; the folding problem in this instance is then much like an ordinary linear protein-
folding problem (with many more degrees of freedom than the restricted case).
2. Interchanging between global and local sampling gives rise to structural collapse that is
too rapid for secondary structure fomiation to occur.
3. The current folding algorithm only models canonical connectivities and correct folding
may depend critically on the existence of one or more non-canonical folding
intermediates (as is experimentally observed in the system of BPTI2"14).
4. The forcefield approximation does not capture the true potential energy minimum for the
system.
Future work on the algorithm will therefore focus on two aspects:
1. Improving the criterion for interchanging global and local sampling.
The algorithm presented in this thesis, by design, attempts to take advantage of both
global and local sampling by intelligently interchanging between dynamic and static
descriptions of bonding. Indeed, the upper limit of protein folding is 20 amino acids and
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solving defensin structures (consisting of 35-40 amino acids) will undoubtedly require a
procedure that utilises restricted conformational space. Future work will focus on
improving the criterion for interchanging between local and global sampling.
2. Introducing non-canonical pairings
The dynamic bond algorithm currently samples canonically connected states only.
Future work will extend the Hamiltonian repertoire to include non-canonical pairings.
8.3. Lipid A-Defensin docking
Bacteria that possess cationic modifications to lipid A are resistant to defensin (and other
antimicrobial attack)15"20.This thesis tests the hypothesis that this resistance arises by virtue of a
simple electrostatic mechanism in which like-charge repulsion disrupts initial (and vital)
defensin-lipid A binding events. Preliminary docking calculations with a simplified
representation of Lipid A - triphosphorylated diglucosamine (TPDG), bis-phsopshrylated
diglucosamine (BPDG) and the cationic mutant aminoarabinose-modified-TPDG (Ara4N) - do
not support a simple, electrostatic repulsion model of antimicrobial resistance. Indeed, only
HBD3 in this model shows any appreciable binding, HBD1 and HBD2 do not. Furthermore, no
strict electrostatic behaviour is observed for F1BD3, implying that the observed binding results
from a complex interplay of hydrogen bonding and electrostatic interactions and not merely a
"simple" charge process as previously postulated)21"25.
Future work will focus on:
1. Expanding the basic model of lipid A to include more regions of the molecule.
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2. Improving docking sampling and applying a more accurate free-energy
procedure to the final free-energy calculation.
3. Performing docking with oligomeric defensins.
4. Obtaining better experimental binding studies to support the in silico modelling.
8.4. p-defensins - A new generation of antibiotic?
Bacterial drug resistance remains a serious problem in the world and there is an urgent
requirement for new and better antibiotics to counter this problem. Explaining antimicrobial
resistance in mutant lipid A bacterial isolates may provide the first insight to the antimicrobial
process. Regrettably, the speculation that preliminary docking between defensin and bacteria
begins with attachments to lipid A is not definitively supported (or rejected) with this model.
Better experimental evidence and more inclusive molecular models will be required to get a
clearer picture of whether or not this interaction occurs.
Assuming that the first, preliminary interactions are elucidated then further questions are
immediately raised: What are the next subsequent events? Do defensins always act as
monomers? Or do they form higher order oligomers that act cooperatively (as is the case with
the complement system26, magainins27"30 and alamethicin31'32)? Do defensins permeate the
bilayer or merely destabilise surface components? How, ultimately, do these small, cationic
peptides create massive macromolecular destabilisation?
The questions posed above require significant resources at both a computational and
experimental level. Answering them may be a matter of life and death for a great many people.
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